[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ffPkBGdq5LCZTV9IIBfzfa3vTuUn_OxYYTkOBRUDARVw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":85,"rows":92},"University of Manitoba",[4],542,false,79,29,97714,35,443,[14,17,20,22,25,28,31,34],{"name":15,"count":16},"Obesity",16,{"name":18,"count":19},"Anxiety",11,{"name":21,"count":19},"Healthy",{"name":23,"count":24},"Depression",10,{"name":26,"count":27},"Type 2 Diabetes",9,{"name":29,"count":30},"Hypercholesterolemia",8,{"name":32,"count":33},"Diabetes Prevention",7,{"name":35,"count":33},"Obesity Prevention",[37,42,47,51,55,60,65,70,75,80],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT05667298","Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer","2025-06-20","Adjuvant Immunoradiotherapy",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06298461","Bowel Preparation for Colonoscopy Among Individuals With Crohn's and Ulcerative Colitis Disease.","2025-12","KleanLyte",{"nctId":48,"briefTitle":49,"date":45,"intervention":50},"NCT07017439","Investigating the Adjunctive Use of Mirabegron in the Early Post-Rezum Procedure Period","Beta-3 agonists",{"nctId":52,"briefTitle":53,"date":45,"intervention":54},"NCT07017452","Trial to Assess the Efficacy and Safety During Convective Radiofrequency Water Vapor Thermal Therapy (REZUM) for Benign Prostate Hyperplasia","Methoxyflurane - Penthrox",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT05337033","Cannabis for Chronic Headaches in Adolescents: the CAN-CHA Trial","2025-12-31","MPL-001",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT06262594","Lemborexant Treatment of Insomnia Linked to Epilepsy","2026-04-18","Lemborexant",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT06478290","Pilot Assessment of the Safety of a Combination of Curcumin, Omega-3, and Vitamin D Supplements in ACPA+ Individuals","2026-07","curcumin, omega-3, and vitamin D",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT03954483","Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal","2026-10-01","Buspirone 10 Mg Oral",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT05119166","International Milk Composition (IMiC) Consortium","2026-10-30","Azithromycin",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT05442840","Evaluation of Pharmacist Intervention for Individuals With Uncontrolled Type 2 Diabetes","2026-12","Behavioral and drugs already approved and available for diabetes management",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,120,138,171,210,232,255,276,294,312,349,371,404,451,487,505,523,548,566,591,614,632,657,684,702,750,768,786,804,822,847,867,890,910,932,950,1001,1037,1073,1098,1116,1134,1160,1185,1203,1229,1247,1272,1297,1315,1340,1366,1384,1407,1436,1454,1472,1490,1514,1548,1584,1609,1632,1650,1676,1702,1720,1750,1777,1795,1821,1839,1864,1888,1924,1960,1985,2011,2029,2053,2078,2096,2120,2146,2168,2193,2218,2242,2260,2285,2312,2337,2361,2387,2418,2449,2472,2498,2516,2542,2560,2585,2603,2626,2650,2675,2699,2724,2751,2769,2793,2811,2834,2856,2880,2906,2924,2948,2966,2984,3002,3026],{"intervention":46,"totalTrials":94,"cells":95},1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":118},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":94,"soonestReadout":45},[107],{"nctId":43,"briefTitle":44,"status":108,"phases":109,"primaryCompletion":45,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":116},"RECRUITING",[90],"2026-05","2024-07-04",418,[114,115],"Crohn Disease","Ulcerative Colitis",[46,117],"Bi-PegLyte",{"trials":119,"activeCount":98},[],{"intervention":117,"totalTrials":94,"cells":121},{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":128,"PHASE4":130,"NA":136},{"trials":123,"activeCount":98},[],{"trials":125,"activeCount":98},[],{"trials":127,"activeCount":98},[],{"trials":129,"activeCount":98},[],{"trials":131,"activeCount":94,"soonestReadout":45},[132],{"nctId":43,"briefTitle":44,"status":108,"phases":133,"primaryCompletion":45,"completion":110,"start":111,"enrollment":112,"conditions":134,"interventions":135},[90],[114,115],[46,117],{"trials":137,"activeCount":98},[],{"intervention":139,"totalTrials":94,"cells":140},"Vancomycin 1000 MG",{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":169},{"trials":142,"activeCount":98},[],{"trials":144,"activeCount":98},[],{"trials":146,"activeCount":98},[],{"trials":148,"activeCount":98},[],{"trials":150,"activeCount":94,"soonestReadout":156},[151],{"nctId":152,"briefTitle":153,"status":154,"phases":155,"primaryCompletion":156,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":168},"NCT06504992","Powdered Intrawound Vancomycin in Open Fractures Trial","NOT_YET_RECRUITING",[90],"2028-09-01","2029-09-01","2024-11-01",350,[161,162,163,164,165,166,167],"Open Fracture","Trauma","Infection, Surgical Site","Fractures, Open","Wound Infection","Fractures, Bone","Post-Operative Wound Infection",[139],{"trials":170,"activeCount":98},[],{"intervention":172,"totalTrials":173,"cells":174},"Heparin",2,{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":181,"PHASE4":206,"NA":208},{"trials":176,"activeCount":98},[],{"trials":178,"activeCount":98},[],{"trials":180,"activeCount":98},[],{"trials":182,"activeCount":94,"soonestReadout":187},[183,194],{"nctId":184,"briefTitle":185,"status":108,"phases":186,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":193},"NCT05848713","AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia",[89],"2028-03-31","2029-03-31","2023-10-10",4000,[192],"Community-acquired Pneumonia",[172],{"nctId":195,"briefTitle":196,"status":197,"phases":198,"primaryCompletion":199,"completion":199,"start":200,"enrollment":201,"conditions":202,"interventions":205},"NCT04372589","Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)","COMPLETED",[88,89],"2021-05-17","2020-05-20",1200,[203,204],"COVID-19","Pneumonia",[172],{"trials":207,"activeCount":98},[],{"trials":209,"activeCount":98},[],{"intervention":50,"totalTrials":94,"cells":211},{"EARLY_PHASE1":212,"PHASE1":214,"PHASE2":216,"PHASE3":218,"PHASE4":228,"NA":230},{"trials":213,"activeCount":98},[],{"trials":215,"activeCount":98},[],{"trials":217,"activeCount":98},[],{"trials":219,"activeCount":94,"soonestReadout":45},[220],{"nctId":48,"briefTitle":49,"status":154,"phases":221,"primaryCompletion":45,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":227},[89],"2026-06","2025-08",50,[226],"Benign Prostate Hypertrophy(BPH)",[50],{"trials":229,"activeCount":98},[],{"trials":231,"activeCount":98},[],{"intervention":64,"totalTrials":94,"cells":233},{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":238,"PHASE3":240,"PHASE4":251,"NA":253},{"trials":235,"activeCount":98},[],{"trials":237,"activeCount":98},[],{"trials":239,"activeCount":98},[],{"trials":241,"activeCount":94,"soonestReadout":63},[242],{"nctId":61,"briefTitle":62,"status":108,"phases":243,"primaryCompletion":63,"completion":244,"start":245,"enrollment":246,"conditions":247,"interventions":250},[89],"2027-04-18","2024-10-29",26,[248,249],"Epilepsy","Sleep",[64],{"trials":252,"activeCount":98},[],{"trials":254,"activeCount":98},[],{"intervention":54,"totalTrials":94,"cells":256},{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":263,"PHASE4":272,"NA":274},{"trials":258,"activeCount":98},[],{"trials":260,"activeCount":98},[],{"trials":262,"activeCount":98},[],{"trials":264,"activeCount":94,"soonestReadout":45},[265],{"nctId":52,"briefTitle":53,"status":154,"phases":266,"primaryCompletion":45,"completion":222,"start":223,"enrollment":267,"conditions":268,"interventions":269},[89],48,[226],[54,270,271],"Percocet Pill","Lorazepam",{"trials":273,"activeCount":98},[],{"trials":275,"activeCount":98},[],{"intervention":270,"totalTrials":94,"cells":277},{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":284,"PHASE4":290,"NA":292},{"trials":279,"activeCount":98},[],{"trials":281,"activeCount":98},[],{"trials":283,"activeCount":98},[],{"trials":285,"activeCount":94,"soonestReadout":45},[286],{"nctId":52,"briefTitle":53,"status":154,"phases":287,"primaryCompletion":45,"completion":222,"start":223,"enrollment":267,"conditions":288,"interventions":289},[89],[226],[54,270,271],{"trials":291,"activeCount":98},[],{"trials":293,"activeCount":98},[],{"intervention":271,"totalTrials":94,"cells":295},{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":300,"PHASE3":302,"PHASE4":308,"NA":310},{"trials":297,"activeCount":98},[],{"trials":299,"activeCount":98},[],{"trials":301,"activeCount":98},[],{"trials":303,"activeCount":94,"soonestReadout":45},[304],{"nctId":52,"briefTitle":53,"status":154,"phases":305,"primaryCompletion":45,"completion":222,"start":223,"enrollment":267,"conditions":306,"interventions":307},[89],[226],[54,270,271],{"trials":309,"activeCount":98},[],{"trials":311,"activeCount":98},[],{"intervention":313,"totalTrials":173,"cells":314},"Standard dressing",{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":319,"PHASE3":343,"PHASE4":345,"NA":347},{"trials":316,"activeCount":98},[],{"trials":318,"activeCount":98},[],{"trials":320,"activeCount":173,"soonestReadout":337},[321,333],{"nctId":322,"briefTitle":323,"status":108,"phases":324,"primaryCompletion":325,"completion":326,"start":327,"enrollment":328,"conditions":329,"interventions":331},"NCT04893863","A Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries",[87,88],"2028-12-31","2029-06-01","2021-10-01",20,[330],"Burns",[313,332],"PluroGel",{"nctId":334,"briefTitle":335,"status":108,"phases":336,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":341,"interventions":342},"NCT05000983","A Between Patient Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries",[87,88],"2028-11-30","2029-12-31","2021-10-20",25,[330],[332,313],{"trials":344,"activeCount":98},[],{"trials":346,"activeCount":98},[],{"trials":348,"activeCount":98},[],{"intervention":332,"totalTrials":173,"cells":350},{"EARLY_PHASE1":351,"PHASE1":353,"PHASE2":355,"PHASE3":365,"PHASE4":367,"NA":369},{"trials":352,"activeCount":98},[],{"trials":354,"activeCount":98},[],{"trials":356,"activeCount":173,"soonestReadout":337},[357,361],{"nctId":322,"briefTitle":323,"status":108,"phases":358,"primaryCompletion":325,"completion":326,"start":327,"enrollment":328,"conditions":359,"interventions":360},[87,88],[330],[313,332],{"nctId":334,"briefTitle":335,"status":108,"phases":362,"primaryCompletion":337,"completion":338,"start":339,"enrollment":340,"conditions":363,"interventions":364},[87,88],[330],[332,313],{"trials":366,"activeCount":98},[],{"trials":368,"activeCount":98},[],{"trials":370,"activeCount":98},[],{"intervention":59,"totalTrials":173,"cells":372},{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":377,"PHASE3":398,"PHASE4":400,"NA":402},{"trials":374,"activeCount":98},[],{"trials":376,"activeCount":98},[],{"trials":378,"activeCount":173,"soonestReadout":58},[379,385],{"nctId":56,"briefTitle":57,"status":108,"phases":380,"primaryCompletion":58,"completion":58,"start":381,"enrollment":328,"conditions":382,"interventions":384},[88],"2024-10-11",[383],"Chronic Migraine",[59],{"nctId":386,"briefTitle":387,"status":154,"phases":388,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":392,"interventions":395},"NCT05754840","CANnabinoids in Pediatric ONCology",[87,88],"2027-03-31","2025-06",60,[393,394],"Childhood Cancer","Cancer",[59,396,397],"MPL-005","MPL-009",{"trials":399,"activeCount":98},[],{"trials":401,"activeCount":98},[],{"trials":403,"activeCount":98},[],{"intervention":405,"totalTrials":406,"cells":407},"Levofloxacin",3,{"EARLY_PHASE1":408,"PHASE1":410,"PHASE2":412,"PHASE3":426,"PHASE4":428,"NA":449},{"trials":409,"activeCount":98},[],{"trials":411,"activeCount":98},[],{"trials":413,"activeCount":94,"soonestReadout":418},[414],{"nctId":415,"briefTitle":416,"status":154,"phases":417,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":421,"interventions":425},"NCT07528417","Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)",[88],"2028-04-30","2026-09-01",75,[422,423,424],"Myeldysplastic Syndrome (MDS)","MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)","Acute Myeloid Leukemia",[405],{"trials":427,"activeCount":98},[],{"trials":429,"activeCount":98},[430,441],{"nctId":431,"briefTitle":432,"status":433,"phases":434,"completion":435,"start":436,"enrollment":437,"conditions":438,"interventions":440},"NCT00245791","Urinary Tract Infection Study With the Antibiotic Levofloxacin Given at a Higher Dose Over a Shorter Period of Time","TERMINATED",[90],"2005-07","2004-10",30,[439],"Complicated Urinary Infection",[405],{"nctId":442,"briefTitle":443,"status":433,"phases":444,"completion":435,"start":445,"enrollment":437,"conditions":446,"interventions":448},"NCT00239161","Safety and Efficacy Study of the Treatment of Kidney Infections With Short Course Levofloxacin",[90],"2004-09",[447],"Acute Uncomplicated Pyelonephritis",[405],{"trials":450,"activeCount":98},[],{"intervention":452,"totalTrials":173,"cells":453},"Tranexamic acid",{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":458,"PHASE3":470,"PHASE4":472,"NA":485},{"trials":455,"activeCount":98},[],{"trials":457,"activeCount":98},[],{"trials":459,"activeCount":94,"soonestReadout":464},[460],{"nctId":461,"briefTitle":462,"status":108,"phases":463,"primaryCompletion":464,"completion":464,"start":465,"enrollment":420,"conditions":466,"interventions":469},"NCT06599762","Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia",[88],"2027-04-01","2025-09-10",[467,424,468],"Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasm",[452],{"trials":471,"activeCount":98},[],{"trials":473,"activeCount":98},[474],{"nctId":475,"briefTitle":476,"status":197,"phases":477,"primaryCompletion":478,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":484},"NCT04803747","A Trial of a Hospital Policy of Tranexamic Acid Use to Reduce Transfusion in Major Non-cardiac Surgery",[90],"2024-03-05","2024-06-03","2022-02-16",8421,[483],"Major Non-cardiac Surgeries",[452],{"trials":486,"activeCount":98},[],{"intervention":396,"totalTrials":94,"cells":488},{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":499,"PHASE4":501,"NA":503},{"trials":490,"activeCount":98},[],{"trials":492,"activeCount":98},[],{"trials":494,"activeCount":94,"soonestReadout":389},[495],{"nctId":386,"briefTitle":387,"status":154,"phases":496,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":497,"interventions":498},[87,88],[393,394],[59,396,397],{"trials":500,"activeCount":98},[],{"trials":502,"activeCount":98},[],{"trials":504,"activeCount":98},[],{"intervention":397,"totalTrials":94,"cells":506},{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":517,"PHASE4":519,"NA":521},{"trials":508,"activeCount":98},[],{"trials":510,"activeCount":98},[],{"trials":512,"activeCount":94,"soonestReadout":389},[513],{"nctId":386,"briefTitle":387,"status":154,"phases":514,"primaryCompletion":389,"completion":389,"start":390,"enrollment":391,"conditions":515,"interventions":516},[87,88],[393,394],[59,396,397],{"trials":518,"activeCount":98},[],{"trials":520,"activeCount":98},[],{"trials":522,"activeCount":98},[],{"intervention":524,"totalTrials":94,"cells":525},"CBD Isolate",{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":542,"PHASE4":544,"NA":546},{"trials":527,"activeCount":98},[],{"trials":529,"activeCount":98},[],{"trials":531,"activeCount":94,"soonestReadout":187},[532],{"nctId":533,"briefTitle":534,"status":154,"phases":535,"primaryCompletion":187,"completion":187,"start":536,"enrollment":537,"conditions":538,"interventions":540},"NCT07023744","CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children",[88],"2025-10-01",90,[539],"Drug Resistant Epilepsy",[524,541],"CBD CHE",{"trials":543,"activeCount":98},[],{"trials":545,"activeCount":98},[],{"trials":547,"activeCount":98},[],{"intervention":541,"totalTrials":94,"cells":549},{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":560,"PHASE4":562,"NA":564},{"trials":551,"activeCount":98},[],{"trials":553,"activeCount":98},[],{"trials":555,"activeCount":94,"soonestReadout":187},[556],{"nctId":533,"briefTitle":534,"status":154,"phases":557,"primaryCompletion":187,"completion":187,"start":536,"enrollment":537,"conditions":558,"interventions":559},[88],[539],[524,541],{"trials":561,"activeCount":98},[],{"trials":563,"activeCount":98},[],{"trials":565,"activeCount":98},[],{"intervention":567,"totalTrials":94,"cells":568},"Phenylephrine",{"EARLY_PHASE1":569,"PHASE1":571,"PHASE2":583,"PHASE3":585,"PHASE4":587,"NA":589},{"trials":570,"activeCount":98},[],{"trials":572,"activeCount":94,"soonestReadout":577},[573],{"nctId":574,"briefTitle":575,"status":108,"phases":576,"primaryCompletion":577,"completion":325,"start":578,"enrollment":579,"conditions":580,"interventions":582},"NCT01731444","Phenylephrine Tumescence for Hemostasis in Surgery for Burn Injury",[87],"2028-06-01","2014-12-01",24,[581],"Blood Loss, Surgical",[567],{"trials":584,"activeCount":98},[],{"trials":586,"activeCount":98},[],{"trials":588,"activeCount":98},[],{"trials":590,"activeCount":98},[],{"intervention":41,"totalTrials":94,"cells":592},{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":606,"PHASE3":608,"PHASE4":610,"NA":612},{"trials":594,"activeCount":98},[],{"trials":596,"activeCount":94,"soonestReadout":40},[597],{"nctId":38,"briefTitle":39,"status":598,"phases":599,"primaryCompletion":40,"completion":600,"start":601,"enrollment":19,"conditions":602,"interventions":604},"ACTIVE_NOT_RECRUITING",[87],"2029-07-01","2023-03-01",[603],"Esophageal Cancer",[41,605],"Adjuvant chemoradiotherapy",{"trials":607,"activeCount":98},[],{"trials":609,"activeCount":98},[],{"trials":611,"activeCount":98},[],{"trials":613,"activeCount":98},[],{"intervention":605,"totalTrials":94,"cells":615},{"EARLY_PHASE1":616,"PHASE1":618,"PHASE2":624,"PHASE3":626,"PHASE4":628,"NA":630},{"trials":617,"activeCount":98},[],{"trials":619,"activeCount":94,"soonestReadout":40},[620],{"nctId":38,"briefTitle":39,"status":598,"phases":621,"primaryCompletion":40,"completion":600,"start":601,"enrollment":19,"conditions":622,"interventions":623},[87],[603],[41,605],{"trials":625,"activeCount":98},[],{"trials":627,"activeCount":98},[],{"trials":629,"activeCount":98},[],{"trials":631,"activeCount":98},[],{"intervention":633,"totalTrials":94,"cells":634},"Nitrous Oxide Inhalant Product",{"EARLY_PHASE1":635,"PHASE1":647,"PHASE2":649,"PHASE3":651,"PHASE4":653,"NA":655},{"trials":636,"activeCount":94,"soonestReadout":641},[637],{"nctId":638,"briefTitle":639,"status":108,"phases":640,"primaryCompletion":641,"completion":642,"start":643,"enrollment":437,"conditions":644,"interventions":646},"NCT03695887","A Pilot Trial of Disposable Nitrous Oxide Canisters in Providing Pain Control During Burn Dressing Changes",[86],"2028-12-01","2029-12-01","2019-10-01",[330,645],"Pain, Acute",[633],{"trials":648,"activeCount":98},[],{"trials":650,"activeCount":98},[],{"trials":652,"activeCount":98},[],{"trials":654,"activeCount":98},[],{"trials":656,"activeCount":98},[],{"intervention":658,"totalTrials":94,"cells":659},"Fluconazole 150 mg",{"EARLY_PHASE1":660,"PHASE1":674,"PHASE2":676,"PHASE3":678,"PHASE4":680,"NA":682},{"trials":661,"activeCount":94,"soonestReadout":666},[662],{"nctId":663,"briefTitle":664,"status":598,"phases":665,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":670,"interventions":672},"NCT04930107","Vulvovaginal Candidiasis in Canadian Females",[86],"2029-04-30","2030-04-30","2021-12-07",120,[671],"Candidiasis, Vulvovaginal",[658,673],"Boric Acid Supp,Vag",{"trials":675,"activeCount":98},[],{"trials":677,"activeCount":98},[],{"trials":679,"activeCount":98},[],{"trials":681,"activeCount":98},[],{"trials":683,"activeCount":98},[],{"intervention":673,"totalTrials":94,"cells":685},{"EARLY_PHASE1":686,"PHASE1":692,"PHASE2":694,"PHASE3":696,"PHASE4":698,"NA":700},{"trials":687,"activeCount":94,"soonestReadout":666},[688],{"nctId":663,"briefTitle":664,"status":598,"phases":689,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":690,"interventions":691},[86],[671],[658,673],{"trials":693,"activeCount":98},[],{"trials":695,"activeCount":98},[],{"trials":697,"activeCount":98},[],{"trials":699,"activeCount":98},[],{"trials":701,"activeCount":98},[],{"intervention":703,"totalTrials":173,"cells":704},"Morphine",{"EARLY_PHASE1":705,"PHASE1":707,"PHASE2":709,"PHASE3":711,"PHASE4":713,"NA":715},{"trials":706,"activeCount":98},[],{"trials":708,"activeCount":98},[],{"trials":710,"activeCount":98},[],{"trials":712,"activeCount":98},[],{"trials":714,"activeCount":98},[],{"trials":716,"activeCount":94,"soonestReadout":721},[717,734],{"nctId":718,"briefTitle":719,"status":108,"phases":720,"primaryCompletion":721,"completion":722,"start":723,"enrollment":724,"conditions":725,"interventions":729},"NCT03715517","Spinal Anesthesia For Enhanced Recovery After Liver Surgery",[91],"2031-07-31","2031-12-31","2018-10-04",128,[726,727,728],"Hepatectomy","Pain, Postoperative","Liver Neoplasms",[730,703,731,732,733],"Bupivacaine 0.75% in Dextrose Inj 8.25%","Bupivacaine 0.25% Preservative-Free Injectable Solution","Bupicavaine 0.125% epidural solution","Hydromorphone 10 mcg\u002FmL epidural solution",{"nctId":735,"briefTitle":736,"status":433,"phases":737,"primaryCompletion":738,"completion":739,"start":740,"enrollment":437,"conditions":741,"interventions":746},"NCT02036697","Hemodynamic Effects of Low Dose Spinal Anesthesia for Cesarean Section",[91],"2014-06","2015-12","2013-11",[742,743,744,745],"Complications; Cesarean Section","Effects of; Anesthesia, Spinal and Epidural, in Pregnancy","Hemodynamic Instability","Personal Satisfaction",[747,748,703,749],"Bupivacaine 4.5","Bupivacaine 9","Fentanyl",{"intervention":730,"totalTrials":94,"cells":751},{"EARLY_PHASE1":752,"PHASE1":754,"PHASE2":756,"PHASE3":758,"PHASE4":760,"NA":762},{"trials":753,"activeCount":98},[],{"trials":755,"activeCount":98},[],{"trials":757,"activeCount":98},[],{"trials":759,"activeCount":98},[],{"trials":761,"activeCount":98},[],{"trials":763,"activeCount":94,"soonestReadout":721},[764],{"nctId":718,"briefTitle":719,"status":108,"phases":765,"primaryCompletion":721,"completion":722,"start":723,"enrollment":724,"conditions":766,"interventions":767},[91],[726,727,728],[730,703,731,732,733],{"intervention":731,"totalTrials":94,"cells":769},{"EARLY_PHASE1":770,"PHASE1":772,"PHASE2":774,"PHASE3":776,"PHASE4":778,"NA":780},{"trials":771,"activeCount":98},[],{"trials":773,"activeCount":98},[],{"trials":775,"activeCount":98},[],{"trials":777,"activeCount":98},[],{"trials":779,"activeCount":98},[],{"trials":781,"activeCount":94,"soonestReadout":721},[782],{"nctId":718,"briefTitle":719,"status":108,"phases":783,"primaryCompletion":721,"completion":722,"start":723,"enrollment":724,"conditions":784,"interventions":785},[91],[726,727,728],[730,703,731,732,733],{"intervention":732,"totalTrials":94,"cells":787},{"EARLY_PHASE1":788,"PHASE1":790,"PHASE2":792,"PHASE3":794,"PHASE4":796,"NA":798},{"trials":789,"activeCount":98},[],{"trials":791,"activeCount":98},[],{"trials":793,"activeCount":98},[],{"trials":795,"activeCount":98},[],{"trials":797,"activeCount":98},[],{"trials":799,"activeCount":94,"soonestReadout":721},[800],{"nctId":718,"briefTitle":719,"status":108,"phases":801,"primaryCompletion":721,"completion":722,"start":723,"enrollment":724,"conditions":802,"interventions":803},[91],[726,727,728],[730,703,731,732,733],{"intervention":733,"totalTrials":94,"cells":805},{"EARLY_PHASE1":806,"PHASE1":808,"PHASE2":810,"PHASE3":812,"PHASE4":814,"NA":816},{"trials":807,"activeCount":98},[],{"trials":809,"activeCount":98},[],{"trials":811,"activeCount":98},[],{"trials":813,"activeCount":98},[],{"trials":815,"activeCount":98},[],{"trials":817,"activeCount":94,"soonestReadout":721},[818],{"nctId":718,"briefTitle":719,"status":108,"phases":819,"primaryCompletion":721,"completion":722,"start":723,"enrollment":724,"conditions":820,"interventions":821},[91],[726,727,728],[730,703,731,732,733],{"intervention":823,"totalTrials":94,"cells":824},"Medical Cannabis",{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":831,"PHASE4":833,"NA":835},{"trials":826,"activeCount":98},[],{"trials":828,"activeCount":98},[],{"trials":830,"activeCount":98},[],{"trials":832,"activeCount":98},[],{"trials":834,"activeCount":98},[],{"trials":836,"activeCount":94,"soonestReadout":841},[837],{"nctId":838,"briefTitle":839,"status":108,"phases":840,"primaryCompletion":841,"completion":841,"start":842,"enrollment":843,"conditions":844,"interventions":846},"NCT05863910","Real World Evidence on the Use of Medical Cannabis in Pediatrics",[],"2027-12-31","2023-11-20",500,[394,248,845],"Neurodevelopmental Disorders",[823],{"intervention":84,"totalTrials":94,"cells":848},{"EARLY_PHASE1":849,"PHASE1":851,"PHASE2":853,"PHASE3":855,"PHASE4":857,"NA":859},{"trials":850,"activeCount":98},[],{"trials":852,"activeCount":98},[],{"trials":854,"activeCount":98},[],{"trials":856,"activeCount":98},[],{"trials":858,"activeCount":98},[],{"trials":860,"activeCount":94,"soonestReadout":83},[861],{"nctId":81,"briefTitle":82,"status":598,"phases":862,"primaryCompletion":83,"completion":83,"start":863,"enrollment":391,"conditions":864,"interventions":866},[91],"2022-07-04",[865],"Diabetes Type 2",[84],{"intervention":79,"totalTrials":94,"cells":868},{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":875,"PHASE4":877,"NA":879},{"trials":870,"activeCount":98},[],{"trials":872,"activeCount":98},[],{"trials":874,"activeCount":98},[],{"trials":876,"activeCount":98},[],{"trials":878,"activeCount":98},[],{"trials":880,"activeCount":94,"soonestReadout":78},[881],{"nctId":76,"briefTitle":77,"status":598,"phases":882,"primaryCompletion":78,"completion":78,"start":883,"enrollment":884,"conditions":885,"interventions":889},[],"2019-11-17",1000,[886,887,888],"Infant Growth","Maternal Health","Infant Nutrition",[79],{"intervention":69,"totalTrials":94,"cells":891},{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":896,"PHASE3":898,"PHASE4":900,"NA":902},{"trials":893,"activeCount":98},[],{"trials":895,"activeCount":98},[],{"trials":897,"activeCount":98},[],{"trials":899,"activeCount":98},[],{"trials":901,"activeCount":98},[],{"trials":903,"activeCount":94,"soonestReadout":68},[904],{"nctId":66,"briefTitle":67,"status":154,"phases":905,"primaryCompletion":68,"completion":906,"start":536,"enrollment":224,"conditions":907,"interventions":909},[91],"2027-10",[908],"Healthy Participants",[69],{"intervention":74,"totalTrials":94,"cells":911},{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":918,"PHASE4":920,"NA":922},{"trials":913,"activeCount":98},[],{"trials":915,"activeCount":98},[],{"trials":917,"activeCount":98},[],{"trials":919,"activeCount":98},[],{"trials":921,"activeCount":98},[],{"trials":923,"activeCount":94,"soonestReadout":73},[924],{"nctId":71,"briefTitle":72,"status":108,"phases":925,"primaryCompletion":73,"completion":926,"start":927,"enrollment":928,"conditions":929,"interventions":930},[91],"2027-10-01","2023-10-16",42,[18],[74,931],"Triazolam 0.25 MG Oral",{"intervention":931,"totalTrials":94,"cells":933},{"EARLY_PHASE1":934,"PHASE1":936,"PHASE2":938,"PHASE3":940,"PHASE4":942,"NA":944},{"trials":935,"activeCount":98},[],{"trials":937,"activeCount":98},[],{"trials":939,"activeCount":98},[],{"trials":941,"activeCount":98},[],{"trials":943,"activeCount":98},[],{"trials":945,"activeCount":94,"soonestReadout":73},[946],{"nctId":71,"briefTitle":72,"status":108,"phases":947,"primaryCompletion":73,"completion":926,"start":927,"enrollment":928,"conditions":948,"interventions":949},[91],[18],[74,931],{"intervention":951,"totalTrials":406,"cells":952},"Dexamethasone",{"EARLY_PHASE1":953,"PHASE1":955,"PHASE2":957,"PHASE3":969,"PHASE4":971,"NA":999},{"trials":954,"activeCount":98},[],{"trials":956,"activeCount":98},[],{"trials":958,"activeCount":98},[959],{"nctId":960,"briefTitle":961,"status":433,"phases":962,"primaryCompletion":963,"completion":963,"start":964,"enrollment":965,"conditions":966,"interventions":968},"NCT00308594","Oral Dexamethasone for the Treatment of Cervical Radiculopathy",[88],"2007-11","2006-11",100,[967],"Cervical Radiculopathy",[951],{"trials":970,"activeCount":98},[],{"trials":972,"activeCount":98},[973,985],{"nctId":974,"briefTitle":975,"status":197,"phases":976,"primaryCompletion":977,"completion":978,"start":979,"enrollment":980,"conditions":981,"interventions":983},"NCT02426736","Effect of Dexamethasone Dose and Route on Duration of Interscalene Block After Outpatient Shoulder Surgery",[90],"2016-07-12","2017-01-12","2015-06-25",280,[727,982],"Disorder of Shoulder",[951,984],"Bupivacaine",{"nctId":986,"briefTitle":987,"status":197,"phases":988,"primaryCompletion":989,"completion":990,"start":991,"enrollment":992,"conditions":993,"interventions":997},"NCT03270033","Intravenous Dexmedetomidine, Dexamethasone and Interscalene Block Duration After Arthroscopic Shoulder Surgery",[90],"2018-04-14","2018-10-13","2017-09-18",198,[727,994,995,996],"Shoulder Joint Disorder","Ambulatory Surgical Procedures","Brachial Plexus Block",[951,998],"Dexmedetomidine",{"trials":1000,"activeCount":98},[],{"intervention":1002,"totalTrials":173,"cells":1003},"Ketamine",{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1010,"PHASE4":1012,"NA":1035},{"trials":1005,"activeCount":98},[],{"trials":1007,"activeCount":98},[],{"trials":1009,"activeCount":98},[],{"trials":1011,"activeCount":98},[],{"trials":1013,"activeCount":98},[1014,1024],{"nctId":1015,"briefTitle":1016,"status":197,"phases":1017,"primaryCompletion":1018,"completion":1018,"start":1019,"enrollment":1020,"conditions":1021,"interventions":1023},"NCT02425202","Ketamine Infusion for Pediatric Patients With Obstructive Sleep Apnea Syndrome (OSAS) After Tonsillectomy",[90],"2018-05-03","2014-12",36,[1022],"Obstructive Sleep Apnea Syndrome",[1002],{"nctId":1025,"briefTitle":1026,"status":1027,"phases":1028,"primaryCompletion":1029,"completion":1030,"start":1031,"enrollment":267,"conditions":1032,"interventions":1033},"NCT02924090","Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression","UNKNOWN",[90],"2017-12","2018-12","2016-09",[23],[1034,1002],"Etomidate",{"trials":1036,"activeCount":98},[],{"intervention":1038,"totalTrials":173,"cells":1039},"nabilone",{"EARLY_PHASE1":1040,"PHASE1":1042,"PHASE2":1044,"PHASE3":1058,"PHASE4":1060,"NA":1071},{"trials":1041,"activeCount":98},[],{"trials":1043,"activeCount":98},[],{"trials":1045,"activeCount":98},[1046],{"nctId":1047,"briefTitle":1048,"status":197,"phases":1049,"primaryCompletion":1050,"completion":1051,"start":1052,"enrollment":224,"conditions":1053,"interventions":1056},"NCT00699634","Nabilone for the Treatment of Phantom Limb Pain",[88],"2011-02","2011-04","2009-01",[1054,1055],"Phantom Limb Pain","Neuropathic Pain",[1057],"Nabilone",{"trials":1059,"activeCount":98},[],{"trials":1061,"activeCount":98},[1062],{"nctId":1063,"briefTitle":1064,"status":197,"phases":1065,"primaryCompletion":1066,"completion":1066,"start":1067,"enrollment":224,"conditions":1068,"interventions":1070},"NCT00480181","Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis",[90],"2012-07","2007-06",[1055,1069],"Multiple Sclerosis",[1038],{"trials":1072,"activeCount":98},[],{"intervention":1074,"totalTrials":94,"cells":1075},"Alteplase \"push\" protocol",{"EARLY_PHASE1":1076,"PHASE1":1078,"PHASE2":1080,"PHASE3":1082,"PHASE4":1084,"NA":1096},{"trials":1077,"activeCount":98},[],{"trials":1079,"activeCount":98},[],{"trials":1081,"activeCount":98},[],{"trials":1083,"activeCount":98},[],{"trials":1085,"activeCount":98},[1086],{"nctId":1087,"briefTitle":1088,"status":433,"phases":1089,"primaryCompletion":1090,"completion":1090,"start":445,"enrollment":1091,"conditions":1092,"interventions":1094},"NCT00303420","Alteplase for Blood Flow Restoration in Hemodialysis Catheters",[90],"2008-12",180,[1093],"Thrombosis",[1074,1095],"alteplase dwell arm",{"trials":1097,"activeCount":98},[],{"intervention":1095,"totalTrials":94,"cells":1099},{"EARLY_PHASE1":1100,"PHASE1":1102,"PHASE2":1104,"PHASE3":1106,"PHASE4":1108,"NA":1114},{"trials":1101,"activeCount":98},[],{"trials":1103,"activeCount":98},[],{"trials":1105,"activeCount":98},[],{"trials":1107,"activeCount":98},[],{"trials":1109,"activeCount":98},[1110],{"nctId":1087,"briefTitle":1088,"status":433,"phases":1111,"primaryCompletion":1090,"completion":1090,"start":445,"enrollment":1091,"conditions":1112,"interventions":1113},[90],[1093],[1074,1095],{"trials":1115,"activeCount":98},[],{"intervention":984,"totalTrials":94,"cells":1117},{"EARLY_PHASE1":1118,"PHASE1":1120,"PHASE2":1122,"PHASE3":1124,"PHASE4":1126,"NA":1132},{"trials":1119,"activeCount":98},[],{"trials":1121,"activeCount":98},[],{"trials":1123,"activeCount":98},[],{"trials":1125,"activeCount":98},[],{"trials":1127,"activeCount":98},[1128],{"nctId":974,"briefTitle":975,"status":197,"phases":1129,"primaryCompletion":977,"completion":978,"start":979,"enrollment":980,"conditions":1130,"interventions":1131},[90],[727,982],[951,984],{"trials":1133,"activeCount":98},[],{"intervention":1135,"totalTrials":94,"cells":1136},"Simethicone 180Mg Cap",{"EARLY_PHASE1":1137,"PHASE1":1139,"PHASE2":1141,"PHASE3":1143,"PHASE4":1145,"NA":1158},{"trials":1138,"activeCount":98},[],{"trials":1140,"activeCount":98},[],{"trials":1142,"activeCount":98},[],{"trials":1144,"activeCount":98},[],{"trials":1146,"activeCount":98},[1147],{"nctId":1148,"briefTitle":1149,"status":197,"phases":1150,"primaryCompletion":1151,"completion":1151,"start":1152,"enrollment":1153,"conditions":1154,"interventions":1157},"NCT03157791","Simethicone and Bowel Preparation in Colonoscopy",[90],"2017-11-26","2017-07-05",471,[1155,1156],"Colonoscopy","Bowel Preparation",[1135],{"trials":1159,"activeCount":98},[],{"intervention":1161,"totalTrials":94,"cells":1162},"amphotericin-B",{"EARLY_PHASE1":1163,"PHASE1":1165,"PHASE2":1167,"PHASE3":1169,"PHASE4":1171,"NA":1183},{"trials":1164,"activeCount":98},[],{"trials":1166,"activeCount":98},[],{"trials":1168,"activeCount":98},[],{"trials":1170,"activeCount":98},[],{"trials":1172,"activeCount":98},[1173],{"nctId":1174,"briefTitle":1175,"status":433,"phases":1176,"primaryCompletion":1177,"completion":1177,"start":1178,"enrollment":173,"conditions":1179,"interventions":1181},"NCT02283905","Amphotericin-B and Voriconazole for Pulmonary Blastomycosis",[90],"2020-09-25","2015-06",[1180],"Blastomycosis",[1161,1182],"voriconazole",{"trials":1184,"activeCount":98},[],{"intervention":1182,"totalTrials":94,"cells":1186},{"EARLY_PHASE1":1187,"PHASE1":1189,"PHASE2":1191,"PHASE3":1193,"PHASE4":1195,"NA":1201},{"trials":1188,"activeCount":98},[],{"trials":1190,"activeCount":98},[],{"trials":1192,"activeCount":98},[],{"trials":1194,"activeCount":98},[],{"trials":1196,"activeCount":98},[1197],{"nctId":1174,"briefTitle":1175,"status":433,"phases":1198,"primaryCompletion":1177,"completion":1177,"start":1178,"enrollment":173,"conditions":1199,"interventions":1200},[90],[1180],[1161,1182],{"trials":1202,"activeCount":98},[],{"intervention":1204,"totalTrials":94,"cells":1205},"Pegylated Interferons (Peg-IFN) and Ribavirin",{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1212,"PHASE4":1214,"NA":1227},{"trials":1207,"activeCount":98},[],{"trials":1209,"activeCount":98},[],{"trials":1211,"activeCount":98},[],{"trials":1213,"activeCount":98},[],{"trials":1215,"activeCount":98},[1216],{"nctId":1217,"briefTitle":1218,"status":197,"phases":1219,"primaryCompletion":1220,"completion":1221,"start":1222,"enrollment":1223,"conditions":1224,"interventions":1226},"NCT00957866","Prospective Anti-Hepatitis C Virus (Anti-HCV) Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian Ethnicity",[90],"2012-10","2012-11","2009-05",160,[1225],"Chronic Hepatitis C",[1204],{"trials":1228,"activeCount":98},[],{"intervention":1034,"totalTrials":94,"cells":1230},{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1235,"PHASE3":1237,"PHASE4":1239,"NA":1245},{"trials":1232,"activeCount":98},[],{"trials":1234,"activeCount":98},[],{"trials":1236,"activeCount":98},[],{"trials":1238,"activeCount":98},[],{"trials":1240,"activeCount":98},[1241],{"nctId":1025,"briefTitle":1026,"status":1027,"phases":1242,"primaryCompletion":1029,"completion":1030,"start":1031,"enrollment":267,"conditions":1243,"interventions":1244},[90],[23],[1034,1002],{"trials":1246,"activeCount":98},[],{"intervention":1248,"totalTrials":94,"cells":1249},"atropine",{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1254,"PHASE3":1256,"PHASE4":1258,"NA":1270},{"trials":1251,"activeCount":98},[],{"trials":1253,"activeCount":98},[],{"trials":1255,"activeCount":98},[],{"trials":1257,"activeCount":98},[],{"trials":1259,"activeCount":98},[1260],{"nctId":1261,"briefTitle":1262,"status":1027,"phases":1263,"primaryCompletion":738,"completion":738,"start":1264,"enrollment":1265,"conditions":1266,"interventions":1269},"NCT01595399","Atropine Versus no Atropine for Neonatal Rapid Sequence Intubation",[90],"2012-04",70,[1267,1268],"Bradycardia","Hypoxemia",[1248],{"trials":1271,"activeCount":98},[],{"intervention":1273,"totalTrials":94,"cells":1274},"sirolimus",{"EARLY_PHASE1":1275,"PHASE1":1277,"PHASE2":1279,"PHASE3":1281,"PHASE4":1283,"NA":1295},{"trials":1276,"activeCount":98},[],{"trials":1278,"activeCount":98},[],{"trials":1280,"activeCount":98},[],{"trials":1282,"activeCount":98},[],{"trials":1284,"activeCount":98},[1285],{"nctId":1286,"briefTitle":1287,"status":197,"phases":1288,"completion":1289,"start":1290,"enrollment":1291,"conditions":1292,"interventions":1294},"NCT00188955","Pilot Study on the Use of Sirolimus to Treat Chronic Allograft Nephropathy in Children After Kidney Transplant",[90],"2008-10","2004-03",40,[1293],"Kidney Transplantation",[1273],{"trials":1296,"activeCount":98},[],{"intervention":998,"totalTrials":94,"cells":1298},{"EARLY_PHASE1":1299,"PHASE1":1301,"PHASE2":1303,"PHASE3":1305,"PHASE4":1307,"NA":1313},{"trials":1300,"activeCount":98},[],{"trials":1302,"activeCount":98},[],{"trials":1304,"activeCount":98},[],{"trials":1306,"activeCount":98},[],{"trials":1308,"activeCount":98},[1309],{"nctId":986,"briefTitle":987,"status":197,"phases":1310,"primaryCompletion":989,"completion":990,"start":991,"enrollment":992,"conditions":1311,"interventions":1312},[90],[727,994,995,996],[951,998],{"trials":1314,"activeCount":98},[],{"intervention":1316,"totalTrials":94,"cells":1317},"tadalafil",{"EARLY_PHASE1":1318,"PHASE1":1320,"PHASE2":1322,"PHASE3":1324,"PHASE4":1326,"NA":1338},{"trials":1319,"activeCount":98},[],{"trials":1321,"activeCount":98},[],{"trials":1323,"activeCount":98},[],{"trials":1325,"activeCount":98},[],{"trials":1327,"activeCount":98},[1328],{"nctId":1329,"briefTitle":1330,"status":197,"phases":1331,"primaryCompletion":1332,"completion":1332,"start":1333,"enrollment":328,"conditions":1334,"interventions":1337},"NCT01067391","Effect of Tadalafil (Cialis) on the Cardiovascular System of Spinal Cord Injury (SCI) Males",[90],"2015-07","2009-10",[1335,1336],"Hypotension","Spinal Cord Injury",[1316],{"trials":1339,"activeCount":98},[],{"intervention":1341,"totalTrials":94,"cells":1342},"Periarticular",{"EARLY_PHASE1":1343,"PHASE1":1345,"PHASE2":1347,"PHASE3":1349,"PHASE4":1351,"NA":1364},{"trials":1344,"activeCount":98},[],{"trials":1346,"activeCount":98},[],{"trials":1348,"activeCount":98},[],{"trials":1350,"activeCount":98},[],{"trials":1352,"activeCount":98},[1353],{"nctId":1354,"briefTitle":1355,"status":1027,"phases":1356,"primaryCompletion":1357,"completion":1358,"start":1359,"enrollment":537,"conditions":1360,"interventions":1362},"NCT00869037","Analgesia After Total Knee Arthroplasty",[90],"2011-07","2012-02","2009-03",[1361],"Analgesia",[1341,1363],"CFNB + Posterior Capsular",{"trials":1365,"activeCount":98},[],{"intervention":1363,"totalTrials":94,"cells":1367},{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1372,"PHASE3":1374,"PHASE4":1376,"NA":1382},{"trials":1369,"activeCount":98},[],{"trials":1371,"activeCount":98},[],{"trials":1373,"activeCount":98},[],{"trials":1375,"activeCount":98},[],{"trials":1377,"activeCount":98},[1378],{"nctId":1354,"briefTitle":1355,"status":1027,"phases":1379,"primaryCompletion":1357,"completion":1358,"start":1359,"enrollment":537,"conditions":1380,"interventions":1381},[90],[1361],[1341,1363],{"trials":1383,"activeCount":98},[],{"intervention":1385,"totalTrials":94,"cells":1386},"Botulinum Toxin-A",{"EARLY_PHASE1":1387,"PHASE1":1389,"PHASE2":1391,"PHASE3":1393,"PHASE4":1395,"NA":1405},{"trials":1388,"activeCount":98},[],{"trials":1390,"activeCount":98},[],{"trials":1392,"activeCount":98},[],{"trials":1394,"activeCount":98},[],{"trials":1396,"activeCount":98},[1397],{"nctId":1398,"briefTitle":1399,"status":197,"phases":1400,"primaryCompletion":1401,"completion":1401,"start":1332,"enrollment":1402,"conditions":1403,"interventions":1404},"NCT02436499","Chronic Migraine Treatment With Botulinum Toxin-A: an Investigation of Functional Magnetic Resonance Imaging Changes.",[90],"2017-03",12,[383],[1385],{"trials":1406,"activeCount":98},[],{"intervention":1408,"totalTrials":94,"cells":1409},"6% aqueous phenol",{"EARLY_PHASE1":1410,"PHASE1":1412,"PHASE2":1414,"PHASE3":1416,"PHASE4":1418,"NA":1434},{"trials":1411,"activeCount":98},[],{"trials":1413,"activeCount":98},[],{"trials":1415,"activeCount":98},[],{"trials":1417,"activeCount":98},[],{"trials":1419,"activeCount":98},[1420],{"nctId":1421,"briefTitle":1422,"status":1027,"phases":1423,"primaryCompletion":1424,"completion":1425,"start":1426,"enrollment":1291,"conditions":1427,"interventions":1430},"NCT06000709","Comparison Between Ultrasound-Guided Genicular Nerve Phenol Neurolysis and Intra-articular Steroid Injections",[90],"2024-01-31","2024-07-31","2023-10-20",[1428,1429],"Osteoarthritis, Knee","Chronic Knee Pain",[1408,1431,1432,1433],"MethylPREDNISolone 40 MG","Intraarticular Knee Placebo","Genicular Nerve Placebo",{"trials":1435,"activeCount":98},[],{"intervention":1431,"totalTrials":94,"cells":1437},{"EARLY_PHASE1":1438,"PHASE1":1440,"PHASE2":1442,"PHASE3":1444,"PHASE4":1446,"NA":1452},{"trials":1439,"activeCount":98},[],{"trials":1441,"activeCount":98},[],{"trials":1443,"activeCount":98},[],{"trials":1445,"activeCount":98},[],{"trials":1447,"activeCount":98},[1448],{"nctId":1421,"briefTitle":1422,"status":1027,"phases":1449,"primaryCompletion":1424,"completion":1425,"start":1426,"enrollment":1291,"conditions":1450,"interventions":1451},[90],[1428,1429],[1408,1431,1432,1433],{"trials":1453,"activeCount":98},[],{"intervention":1432,"totalTrials":94,"cells":1455},{"EARLY_PHASE1":1456,"PHASE1":1458,"PHASE2":1460,"PHASE3":1462,"PHASE4":1464,"NA":1470},{"trials":1457,"activeCount":98},[],{"trials":1459,"activeCount":98},[],{"trials":1461,"activeCount":98},[],{"trials":1463,"activeCount":98},[],{"trials":1465,"activeCount":98},[1466],{"nctId":1421,"briefTitle":1422,"status":1027,"phases":1467,"primaryCompletion":1424,"completion":1425,"start":1426,"enrollment":1291,"conditions":1468,"interventions":1469},[90],[1428,1429],[1408,1431,1432,1433],{"trials":1471,"activeCount":98},[],{"intervention":1433,"totalTrials":94,"cells":1473},{"EARLY_PHASE1":1474,"PHASE1":1476,"PHASE2":1478,"PHASE3":1480,"PHASE4":1482,"NA":1488},{"trials":1475,"activeCount":98},[],{"trials":1477,"activeCount":98},[],{"trials":1479,"activeCount":98},[],{"trials":1481,"activeCount":98},[],{"trials":1483,"activeCount":98},[1484],{"nctId":1421,"briefTitle":1422,"status":1027,"phases":1485,"primaryCompletion":1424,"completion":1425,"start":1426,"enrollment":1291,"conditions":1486,"interventions":1487},[90],[1428,1429],[1408,1431,1432,1433],{"trials":1489,"activeCount":98},[],{"intervention":1491,"totalTrials":94,"cells":1492},"Tacrolimus",{"EARLY_PHASE1":1493,"PHASE1":1495,"PHASE2":1497,"PHASE3":1499,"PHASE4":1501,"NA":1512},{"trials":1494,"activeCount":98},[],{"trials":1496,"activeCount":98},[],{"trials":1498,"activeCount":98},[],{"trials":1500,"activeCount":98},[],{"trials":1502,"activeCount":98},[1503],{"nctId":1504,"briefTitle":1505,"status":197,"phases":1506,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":328,"conditions":1509,"interventions":1511},"NCT04237246","Comparative FK506 Drug Levels of Once Daily Advagraf in First Nations and Caucasian Patients With Liver Transplants",[90],"2019-11-27","2015-04",[1510],"Liver Failure",[1491],{"trials":1513,"activeCount":98},[],{"intervention":1515,"totalTrials":173,"cells":1516},"Pregabalin",{"EARLY_PHASE1":1517,"PHASE1":1519,"PHASE2":1521,"PHASE3":1523,"PHASE4":1544,"NA":1546},{"trials":1518,"activeCount":98},[],{"trials":1520,"activeCount":98},[],{"trials":1522,"activeCount":98},[],{"trials":1524,"activeCount":98},[1525,1535],{"nctId":1526,"briefTitle":1527,"status":1027,"phases":1528,"primaryCompletion":1529,"completion":1530,"start":1531,"enrollment":1291,"conditions":1532,"interventions":1534},"NCT00623285","The Effects of Peri-operative Pregabalin Administration on Post-operative Analgesia in Patients Undergoing Coronary Bypass Grafting",[89],"2011-03","2011-06","2008-04",[1533],"Postoperative Pain.",[1515],{"nctId":1536,"briefTitle":1537,"status":197,"phases":1538,"primaryCompletion":1066,"completion":1066,"start":1539,"enrollment":420,"conditions":1540,"interventions":1541},"NCT00291148","Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic Pain",[89],"2006-03",[1055,1069],[1542,1543],"paroxetine","pregabalin",{"trials":1545,"activeCount":98},[],{"trials":1547,"activeCount":98},[],{"intervention":1549,"totalTrials":173,"cells":1550},"nabilone 0.5 mg",{"EARLY_PHASE1":1551,"PHASE1":1553,"PHASE2":1555,"PHASE3":1566,"PHASE4":1580,"NA":1582},{"trials":1552,"activeCount":98},[],{"trials":1554,"activeCount":98},[],{"trials":1556,"activeCount":98},[1557],{"nctId":1558,"briefTitle":1559,"status":197,"phases":1560,"primaryCompletion":1561,"completion":1561,"start":1562,"enrollment":1402,"conditions":1563,"interventions":1565},"NCT01222468","Effect of Cannabinoids on Spasticity and Neuropathic Pain in Spinal Cord Injured Persons",[88],"2015-02","2012-06",[1564],"Muscle Spasticity as a Result of Spinal Cord Injury",[1549],{"trials":1567,"activeCount":98},[1568],{"nctId":1569,"briefTitle":1570,"status":197,"phases":1571,"primaryCompletion":1572,"completion":1572,"start":1573,"enrollment":1574,"conditions":1575,"interventions":1578},"NCT05180968","DIalysis Symptom COntrol-Pruritus Outcome Trial",[89],"2023-08-11","2022-08-02",14,[1576,1577],"End Stage Renal Disease","Pruritus",[1579],"Nabilone 0.5 MG Oral",{"trials":1581,"activeCount":98},[],{"trials":1583,"activeCount":98},[],{"intervention":1585,"totalTrials":94,"cells":1586},"0.15 mg\u002Fkg dexamethasone",{"EARLY_PHASE1":1587,"PHASE1":1589,"PHASE2":1591,"PHASE3":1593,"PHASE4":1605,"NA":1607},{"trials":1588,"activeCount":98},[],{"trials":1590,"activeCount":98},[],{"trials":1592,"activeCount":98},[],{"trials":1594,"activeCount":98},[1595],{"nctId":1596,"briefTitle":1597,"status":197,"phases":1598,"primaryCompletion":1599,"completion":1600,"start":1601,"enrollment":224,"conditions":1602,"interventions":1604},"NCT06272383","Croup Dosing Study",[89],"2025-01-28","2025-02-20","2024-06-05",[1603],"Croup",[1585],{"trials":1606,"activeCount":98},[],{"trials":1608,"activeCount":98},[],{"intervention":1610,"totalTrials":94,"cells":1611},"Epidural Catheter 0.2% ropivacaine",{"EARLY_PHASE1":1612,"PHASE1":1614,"PHASE2":1616,"PHASE3":1618,"PHASE4":1628,"NA":1630},{"trials":1613,"activeCount":98},[],{"trials":1615,"activeCount":98},[],{"trials":1617,"activeCount":98},[],{"trials":1619,"activeCount":98},[1620],{"nctId":1621,"briefTitle":1622,"status":433,"phases":1623,"primaryCompletion":740,"completion":740,"start":1220,"enrollment":1624,"conditions":1625,"interventions":1626},"NCT01700491","Pilot Study: Paravertebral Analgesia vs Epidural Analgesia After Thoracotomy",[89],21,[1335],[1610,1627],"Paravertebral Catheter 0.4% ropivacaine",{"trials":1629,"activeCount":98},[],{"trials":1631,"activeCount":98},[],{"intervention":1627,"totalTrials":94,"cells":1633},{"EARLY_PHASE1":1634,"PHASE1":1636,"PHASE2":1638,"PHASE3":1640,"PHASE4":1646,"NA":1648},{"trials":1635,"activeCount":98},[],{"trials":1637,"activeCount":98},[],{"trials":1639,"activeCount":98},[],{"trials":1641,"activeCount":98},[1642],{"nctId":1621,"briefTitle":1622,"status":433,"phases":1643,"primaryCompletion":740,"completion":740,"start":1220,"enrollment":1624,"conditions":1644,"interventions":1645},[89],[1335],[1610,1627],{"trials":1647,"activeCount":98},[],{"trials":1649,"activeCount":98},[],{"intervention":1651,"totalTrials":94,"cells":1652},"99mTc MDP Injection:neutron-bombardment",{"EARLY_PHASE1":1653,"PHASE1":1655,"PHASE2":1657,"PHASE3":1659,"PHASE4":1672,"NA":1674},{"trials":1654,"activeCount":98},[],{"trials":1656,"activeCount":98},[],{"trials":1658,"activeCount":98},[],{"trials":1660,"activeCount":98},[1661],{"nctId":1662,"briefTitle":1663,"status":433,"phases":1664,"primaryCompletion":1665,"completion":1666,"start":1667,"enrollment":1668,"conditions":1669,"interventions":1671},"NCT03002454","Sodium Pertechnetate (99Tc) Injection Generator: 99mTc From Neutron-activation 99Mo v 99mTc From Fission 99Mo",[89],"2016-11","2017-01","2016-08",4,[1670],"Cancer of Bone",[1651],{"trials":1673,"activeCount":98},[],{"trials":1675,"activeCount":98},[],{"intervention":1677,"totalTrials":94,"cells":1678},"Theophylline",{"EARLY_PHASE1":1679,"PHASE1":1681,"PHASE2":1683,"PHASE3":1685,"PHASE4":1698,"NA":1700},{"trials":1680,"activeCount":98},[],{"trials":1682,"activeCount":98},[],{"trials":1684,"activeCount":98},[],{"trials":1686,"activeCount":98},[1687],{"nctId":1688,"briefTitle":1689,"status":197,"phases":1690,"primaryCompletion":1691,"completion":1692,"start":1693,"enrollment":1694,"conditions":1695,"interventions":1697},"NCT01066728","CO2 Inhalation as a New Treatment Modality for Apnea of Prematurity",[88,89],"2005-09","2007-03","2001-08",87,[1696],"Apnea of Prematurity",[1677],{"trials":1699,"activeCount":98},[],{"trials":1701,"activeCount":98},[],{"intervention":1542,"totalTrials":94,"cells":1703},{"EARLY_PHASE1":1704,"PHASE1":1706,"PHASE2":1708,"PHASE3":1710,"PHASE4":1716,"NA":1718},{"trials":1705,"activeCount":98},[],{"trials":1707,"activeCount":98},[],{"trials":1709,"activeCount":98},[],{"trials":1711,"activeCount":98},[1712],{"nctId":1536,"briefTitle":1537,"status":197,"phases":1713,"primaryCompletion":1066,"completion":1066,"start":1539,"enrollment":420,"conditions":1714,"interventions":1715},[89],[1055,1069],[1542,1543],{"trials":1717,"activeCount":98},[],{"trials":1719,"activeCount":98},[],{"intervention":1721,"totalTrials":94,"cells":1722},"Eutectic mixture of local anesthetics",{"EARLY_PHASE1":1723,"PHASE1":1725,"PHASE2":1727,"PHASE3":1729,"PHASE4":1746,"NA":1748},{"trials":1724,"activeCount":98},[],{"trials":1726,"activeCount":98},[],{"trials":1728,"activeCount":98},[],{"trials":1730,"activeCount":98},[1731],{"nctId":1732,"briefTitle":1733,"status":1027,"phases":1734,"primaryCompletion":1735,"completion":1736,"start":1737,"enrollment":1738,"conditions":1739,"interventions":1745},"NCT06242977","Efficacy of EMLA Cream Assisted Loco-sedation for Office-based Andrology Procedures",[89],"2024-08-15","2024-08-30","2024-01-25",72,[1740,1741,1742,1743,1744],"Scrotum Disease","Hydrocele Male","Spermatocele","Scrotal Hematocele","Local Anesthesia",[1721],{"trials":1747,"activeCount":98},[],{"trials":1749,"activeCount":98},[],{"intervention":1751,"totalTrials":94,"cells":1752},"1,4-Diaminobutane",{"EARLY_PHASE1":1753,"PHASE1":1755,"PHASE2":1757,"PHASE3":1759,"PHASE4":1773,"NA":1775},{"trials":1754,"activeCount":98},[],{"trials":1756,"activeCount":98},[],{"trials":1758,"activeCount":98},[],{"trials":1760,"activeCount":98},[1761],{"nctId":1762,"briefTitle":1763,"status":197,"phases":1764,"primaryCompletion":1765,"completion":1766,"start":1767,"enrollment":1768,"conditions":1769,"interventions":1771},"NCT03376620","Role of Topical Putrescine (Fibrostat) for Prevention of Hypertrophic Scars in Mammoplasty Patients",[89],"2013-08-13","2016-07-15","2011-09-02",56,[1770],"Hypertrophic Scar",[1751,1772],"10% Urea cream",{"trials":1774,"activeCount":98},[],{"trials":1776,"activeCount":98},[],{"intervention":1772,"totalTrials":94,"cells":1778},{"EARLY_PHASE1":1779,"PHASE1":1781,"PHASE2":1783,"PHASE3":1785,"PHASE4":1791,"NA":1793},{"trials":1780,"activeCount":98},[],{"trials":1782,"activeCount":98},[],{"trials":1784,"activeCount":98},[],{"trials":1786,"activeCount":98},[1787],{"nctId":1762,"briefTitle":1763,"status":197,"phases":1788,"primaryCompletion":1765,"completion":1766,"start":1767,"enrollment":1768,"conditions":1789,"interventions":1790},[89],[1770],[1751,1772],{"trials":1792,"activeCount":98},[],{"trials":1794,"activeCount":98},[],{"intervention":1796,"totalTrials":94,"cells":1797},"Freeze Dried Bone Allograft",{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1804,"PHASE4":1817,"NA":1819},{"trials":1799,"activeCount":98},[],{"trials":1801,"activeCount":98},[],{"trials":1803,"activeCount":98},[],{"trials":1805,"activeCount":98},[1806],{"nctId":1807,"briefTitle":1808,"status":197,"phases":1809,"primaryCompletion":1810,"completion":1810,"start":1811,"enrollment":246,"conditions":1812,"interventions":1815},"NCT03331185","Changes of Soft and Hard Tissues After Alveolar Ridge Preservation: Freeze-dried Bone Allograft vs. L-PRF Clot",[88,89],"2019-04-02","2018-01-03",[1813,1814],"Alveolar Bone Loss","Tooth Loss",[1796,1816],"L-PRF clot",{"trials":1818,"activeCount":98},[],{"trials":1820,"activeCount":98},[],{"intervention":1816,"totalTrials":94,"cells":1822},{"EARLY_PHASE1":1823,"PHASE1":1825,"PHASE2":1827,"PHASE3":1829,"PHASE4":1835,"NA":1837},{"trials":1824,"activeCount":98},[],{"trials":1826,"activeCount":98},[],{"trials":1828,"activeCount":98},[],{"trials":1830,"activeCount":98},[1831],{"nctId":1807,"briefTitle":1808,"status":197,"phases":1832,"primaryCompletion":1810,"completion":1810,"start":1811,"enrollment":246,"conditions":1833,"interventions":1834},[88,89],[1813,1814],[1796,1816],{"trials":1836,"activeCount":98},[],{"trials":1838,"activeCount":98},[],{"intervention":1840,"totalTrials":94,"cells":1841},"Methylprednisolone",{"EARLY_PHASE1":1842,"PHASE1":1844,"PHASE2":1846,"PHASE3":1848,"PHASE4":1860,"NA":1862},{"trials":1843,"activeCount":98},[],{"trials":1845,"activeCount":98},[],{"trials":1847,"activeCount":98},[],{"trials":1849,"activeCount":98},[1850],{"nctId":1851,"briefTitle":1852,"status":197,"phases":1853,"primaryCompletion":1854,"completion":1855,"start":1856,"enrollment":9,"conditions":1857,"interventions":1859},"NCT05951504","The Prospective Evaluation of Peri-Operative Glucocorticoid Use in the Management of Cervicofacial Infections of Odontogenic Origin",[88,89],"2023-03-30","2023-07-01","2022-06-22",[1858],"Odontogenic Infection of Jaw (Disorder)",[1840],{"trials":1861,"activeCount":98},[],{"trials":1863,"activeCount":98},[],{"intervention":1865,"totalTrials":94,"cells":1866},"liraglutide",{"EARLY_PHASE1":1867,"PHASE1":1869,"PHASE2":1871,"PHASE3":1873,"PHASE4":1884,"NA":1886},{"trials":1868,"activeCount":98},[],{"trials":1870,"activeCount":98},[],{"trials":1872,"activeCount":98},[],{"trials":1874,"activeCount":98},[1875],{"nctId":1876,"briefTitle":1877,"status":433,"phases":1878,"primaryCompletion":1879,"completion":1879,"start":1880,"enrollment":1881,"conditions":1882,"interventions":1883},"NCT01628445","Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin",[89],"2015-11","2012-08",52,[26],[1865],{"trials":1885,"activeCount":98},[],{"trials":1887,"activeCount":98},[],{"intervention":1889,"totalTrials":173,"cells":1890},"Botulinum Toxin Type A",{"EARLY_PHASE1":1891,"PHASE1":1893,"PHASE2":1895,"PHASE3":1918,"PHASE4":1920,"NA":1922},{"trials":1892,"activeCount":98},[],{"trials":1894,"activeCount":98},[],{"trials":1896,"activeCount":98},[1897,1908],{"nctId":1898,"briefTitle":1899,"status":433,"phases":1900,"primaryCompletion":1901,"completion":1902,"start":1903,"enrollment":1402,"conditions":1904,"interventions":1906},"NCT01911377","Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS",[88],"2015-05","2015-08","2013-10",[1055,1905],"Allodynia",[1889,1907],"Normal Saline for",{"nctId":1909,"briefTitle":1910,"status":1027,"phases":1911,"primaryCompletion":1912,"completion":1913,"start":1914,"enrollment":1291,"conditions":1915,"interventions":1917},"NCT02810015","Treatment of Temporo-Myofascial Disorder of Muscular Origin Using Botulinum Toxin: A Prospective Study",[88],"2018-07","2019-06","2016-07",[1916],"Temporo-Myofascial Disorder",[1889],{"trials":1919,"activeCount":98},[],{"trials":1921,"activeCount":98},[],{"trials":1923,"activeCount":98},[],{"intervention":1925,"totalTrials":173,"cells":1926},"Unfractionated heparin",{"EARLY_PHASE1":1927,"PHASE1":1929,"PHASE2":1931,"PHASE3":1954,"PHASE4":1956,"NA":1958},{"trials":1928,"activeCount":98},[],{"trials":1930,"activeCount":98},[],{"trials":1932,"activeCount":98},[1933,1944],{"nctId":1934,"briefTitle":1935,"status":433,"phases":1936,"primaryCompletion":1937,"completion":1937,"start":1938,"enrollment":1939,"conditions":1940,"interventions":1943},"NCT03378466","Heparin Anticoagulation in Septic Shock",[88],"2021-12-31","2018-03-12",178,[1941,1942],"Septic Shock","Vasodilatory Shock",[1925],{"nctId":1945,"briefTitle":1946,"status":197,"phases":1947,"primaryCompletion":1948,"completion":1949,"start":1066,"enrollment":1950,"conditions":1951,"interventions":1952},"NCT01648036","Heparin Anticoagulation to Improve Outcomes in Septic Shock: The HALO Pilot",[88],"2014-01","2014-02",76,[1941],[1925,1953],"Dalteparin",{"trials":1955,"activeCount":98},[],{"trials":1957,"activeCount":98},[],{"trials":1959,"activeCount":98},[],{"intervention":1961,"totalTrials":94,"cells":1962},"Methoxyflurane",{"EARLY_PHASE1":1963,"PHASE1":1965,"PHASE2":1967,"PHASE3":1979,"PHASE4":1981,"NA":1983},{"trials":1964,"activeCount":98},[],{"trials":1966,"activeCount":98},[],{"trials":1968,"activeCount":98},[1969],{"nctId":1970,"briefTitle":1971,"status":197,"phases":1972,"primaryCompletion":1973,"completion":1974,"start":1975,"enrollment":1291,"conditions":1976,"interventions":1978},"NCT07192198","Efficacy of Inhaled Methoxyflurane (Penthrox) as Adjunct for Urologic Procedures Under Local Anesthetic: A Pilot Study",[88],"2024-11-27","2024-12-19","2024-04-17",[1740,1741,1742,1743,1977],"Anesthesia, Local",[1961],{"trials":1980,"activeCount":98},[],{"trials":1982,"activeCount":98},[],{"trials":1984,"activeCount":98},[],{"intervention":1986,"totalTrials":94,"cells":1987},"Oral dexamethasone",{"EARLY_PHASE1":1988,"PHASE1":1990,"PHASE2":1992,"PHASE3":2005,"PHASE4":2007,"NA":2009},{"trials":1989,"activeCount":98},[],{"trials":1991,"activeCount":98},[],{"trials":1993,"activeCount":98},[1994],{"nctId":1995,"briefTitle":1996,"status":1027,"phases":1997,"primaryCompletion":1998,"completion":1178,"start":1999,"enrollment":2000,"conditions":2001,"interventions":2003},"NCT02234466","Preoperative Oral Dexamethasone to Improve Recovery After Surgery",[88],"2015-03","2014-08",80,[2002],"Breast Cancer",[1986,2004],"Ondansetron",{"trials":2006,"activeCount":98},[],{"trials":2008,"activeCount":98},[],{"trials":2010,"activeCount":98},[],{"intervention":2004,"totalTrials":94,"cells":2012},{"EARLY_PHASE1":2013,"PHASE1":2015,"PHASE2":2017,"PHASE3":2023,"PHASE4":2025,"NA":2027},{"trials":2014,"activeCount":98},[],{"trials":2016,"activeCount":98},[],{"trials":2018,"activeCount":98},[2019],{"nctId":1995,"briefTitle":1996,"status":1027,"phases":2020,"primaryCompletion":1998,"completion":1178,"start":1999,"enrollment":2000,"conditions":2021,"interventions":2022},[88],[2002],[1986,2004],{"trials":2024,"activeCount":98},[],{"trials":2026,"activeCount":98},[],{"trials":2028,"activeCount":98},[],{"intervention":2030,"totalTrials":94,"cells":2031},"nabilone then placebo",{"EARLY_PHASE1":2032,"PHASE1":2034,"PHASE2":2036,"PHASE3":2047,"PHASE4":2049,"NA":2051},{"trials":2033,"activeCount":98},[],{"trials":2035,"activeCount":98},[],{"trials":2037,"activeCount":98},[2038],{"nctId":2039,"briefTitle":2040,"status":197,"phases":2041,"primaryCompletion":963,"completion":2042,"start":2043,"conditions":2044,"interventions":2046},"NCT00623376","Randomized Double Blind Cross Over Study for Nabilone in Spasticity in Spinal Cord Injury Persons",[88],"2007-12","2007-07",[2045],"Spasticity in Spinal Cord Injured Persons",[2030],{"trials":2048,"activeCount":98},[],{"trials":2050,"activeCount":98},[],{"trials":2052,"activeCount":98},[],{"intervention":2054,"totalTrials":94,"cells":2055},"Oseltamivir",{"EARLY_PHASE1":2056,"PHASE1":2058,"PHASE2":2060,"PHASE3":2072,"PHASE4":2074,"NA":2076},{"trials":2057,"activeCount":98},[],{"trials":2059,"activeCount":98},[],{"trials":2061,"activeCount":98},[2062],{"nctId":2063,"briefTitle":2064,"status":433,"phases":2065,"primaryCompletion":2066,"completion":2066,"start":2067,"enrollment":2068,"conditions":2069,"interventions":2071},"NCT01010087","Trial Comparing High Versus Standard Dose Oseltamivir in Severe Influenza Infection in ICU",[88],"2011-05","2009-11",59,[2070],"Influenza A Virus",[2054],{"trials":2073,"activeCount":98},[],{"trials":2075,"activeCount":98},[],{"trials":2077,"activeCount":98},[],{"intervention":1907,"totalTrials":94,"cells":2079},{"EARLY_PHASE1":2080,"PHASE1":2082,"PHASE2":2084,"PHASE3":2090,"PHASE4":2092,"NA":2094},{"trials":2081,"activeCount":98},[],{"trials":2083,"activeCount":98},[],{"trials":2085,"activeCount":98},[2086],{"nctId":1898,"briefTitle":1899,"status":433,"phases":2087,"primaryCompletion":1901,"completion":1902,"start":1903,"enrollment":1402,"conditions":2088,"interventions":2089},[88],[1055,1905],[1889,1907],{"trials":2091,"activeCount":98},[],{"trials":2093,"activeCount":98},[],{"trials":2095,"activeCount":98},[],{"intervention":2097,"totalTrials":94,"cells":2098},"Baclofen",{"EARLY_PHASE1":2099,"PHASE1":2101,"PHASE2":2103,"PHASE3":2114,"PHASE4":2116,"NA":2118},{"trials":2100,"activeCount":98},[],{"trials":2102,"activeCount":98},[],{"trials":2104,"activeCount":98},[2105],{"nctId":2106,"briefTitle":2107,"status":2108,"phases":2109,"primaryCompletion":2110,"completion":2110,"start":2043,"enrollment":98,"conditions":2111,"interventions":2113},"NCT00493428","Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study","WITHDRAWN",[88],"2011-01",[2112],"Hepatocellular Carcinoma",[2097],{"trials":2115,"activeCount":98},[],{"trials":2117,"activeCount":98},[],{"trials":2119,"activeCount":98},[],{"intervention":2121,"totalTrials":94,"cells":2122},"Budesonide in bovine lipid extract surfactant",{"EARLY_PHASE1":2123,"PHASE1":2125,"PHASE2":2127,"PHASE3":2140,"PHASE4":2142,"NA":2144},{"trials":2124,"activeCount":98},[],{"trials":2126,"activeCount":98},[],{"trials":2128,"activeCount":98},[2129],{"nctId":2130,"briefTitle":2131,"status":1027,"phases":2132,"primaryCompletion":2133,"completion":2134,"start":2135,"enrollment":437,"conditions":2136,"interventions":2139},"NCT04019106","Budesonide With Intratracheal Surfactants in Extremely Preterm Infants",[87,88],"2020-10-15","2021-01-15","2019-10-15",[2137,2138],"Bronchopulmonary Dysplasia","Respiratory Distress Syndrome in Premature Infant",[2121],{"trials":2141,"activeCount":98},[],{"trials":2143,"activeCount":98},[],{"trials":2145,"activeCount":98},[],{"intervention":2147,"totalTrials":94,"cells":2148},"Denosumab",{"EARLY_PHASE1":2149,"PHASE1":2151,"PHASE2":2153,"PHASE3":2162,"PHASE4":2164,"NA":2166},{"trials":2150,"activeCount":98},[],{"trials":2152,"activeCount":98},[],{"trials":2154,"activeCount":98},[2155],{"nctId":2156,"briefTitle":2157,"status":197,"phases":2158,"primaryCompletion":2159,"completion":2159,"start":1561,"enrollment":173,"conditions":2160,"interventions":2161},"NCT02321280","The Efficacy of Denosumab in Active Crohn's Disease",[87,88],"2018-04-20",[114],[2147],{"trials":2163,"activeCount":98},[],{"trials":2165,"activeCount":98},[],{"trials":2167,"activeCount":98},[],{"intervention":2169,"totalTrials":94,"cells":2170},"Indomethacin",{"EARLY_PHASE1":2171,"PHASE1":2173,"PHASE2":2175,"PHASE3":2187,"PHASE4":2189,"NA":2191},{"trials":2172,"activeCount":98},[],{"trials":2174,"activeCount":98},[],{"trials":2176,"activeCount":98},[2177],{"nctId":2178,"briefTitle":2179,"status":2108,"phases":2180,"primaryCompletion":2181,"completion":2182,"start":2183,"enrollment":98,"conditions":2184,"interventions":2186},"NCT04025177","Indomethacin PK-PD in Extremely Preterm Neonates",[88],"2021-08","2022-02","2020-01",[2185],"Patent Ductus Arteriosus After Premature Birth",[2169],{"trials":2188,"activeCount":98},[],{"trials":2190,"activeCount":98},[],{"trials":2192,"activeCount":98},[],{"intervention":2194,"totalTrials":94,"cells":2195},"Ingestion of a 200 mg dose of amantadine hydrochloride",{"EARLY_PHASE1":2196,"PHASE1":2198,"PHASE2":2200,"PHASE3":2212,"PHASE4":2214,"NA":2216},{"trials":2197,"activeCount":98},[],{"trials":2199,"activeCount":98},[],{"trials":2201,"activeCount":98},[2202],{"nctId":2203,"briefTitle":2204,"status":197,"phases":2205,"primaryCompletion":2206,"completion":2207,"start":2208,"enrollment":2209,"conditions":2210,"interventions":2211},"NCT00755898","Urinary Excretion of Acetylamantadine by Cancer Patients",[88],"2008-06","2008-07","2003-12",150,[394],[2194,2194],{"trials":2213,"activeCount":98},[],{"trials":2215,"activeCount":98},[],{"trials":2217,"activeCount":98},[],{"intervention":2219,"totalTrials":94,"cells":2220},"Cyclophosphamide",{"EARLY_PHASE1":2221,"PHASE1":2223,"PHASE2":2225,"PHASE3":2236,"PHASE4":2238,"NA":2240},{"trials":2222,"activeCount":98},[],{"trials":2224,"activeCount":98},[],{"trials":2226,"activeCount":98},[2227],{"nctId":2228,"briefTitle":2229,"status":433,"phases":2230,"primaryCompletion":2231,"completion":2231,"start":2232,"enrollment":1668,"conditions":2233,"interventions":2235},"NCT01630538","Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection (AMR) in Kidney Transplants",[88],"2018-01-18","2013-06",[2234],"Antibody Mediated Rejection",[2219],{"trials":2237,"activeCount":98},[],{"trials":2239,"activeCount":98},[],{"trials":2241,"activeCount":98},[],{"intervention":1953,"totalTrials":94,"cells":2243},{"EARLY_PHASE1":2244,"PHASE1":2246,"PHASE2":2248,"PHASE3":2254,"PHASE4":2256,"NA":2258},{"trials":2245,"activeCount":98},[],{"trials":2247,"activeCount":98},[],{"trials":2249,"activeCount":98},[2250],{"nctId":1945,"briefTitle":1946,"status":197,"phases":2251,"primaryCompletion":1948,"completion":1949,"start":1066,"enrollment":1950,"conditions":2252,"interventions":2253},[88],[1941],[1925,1953],{"trials":2255,"activeCount":98},[],{"trials":2257,"activeCount":98},[],{"trials":2259,"activeCount":98},[],{"intervention":2261,"totalTrials":94,"cells":2262},"Cycloserine",{"EARLY_PHASE1":2263,"PHASE1":2265,"PHASE2":2277,"PHASE3":2279,"PHASE4":2281,"NA":2283},{"trials":2264,"activeCount":98},[],{"trials":2266,"activeCount":98},[2267],{"nctId":2268,"briefTitle":2269,"status":433,"phases":2270,"primaryCompletion":2271,"completion":1665,"start":2272,"enrollment":2273,"conditions":2274,"interventions":2276},"NCT02735694","Cycloserine in the Treatment of Sleep Apnea",[87],"2016-06","2015-09",18,[2275],"Sleep Apnea Syndromes",[2261],{"trials":2278,"activeCount":98},[],{"trials":2280,"activeCount":98},[],{"trials":2282,"activeCount":98},[],{"trials":2284,"activeCount":98},[],{"intervention":2286,"totalTrials":94,"cells":2287},"FVH1 - a DNA-based influenza vaccine",{"EARLY_PHASE1":2288,"PHASE1":2290,"PHASE2":2304,"PHASE3":2306,"PHASE4":2308,"NA":2310},{"trials":2289,"activeCount":98},[],{"trials":2291,"activeCount":98},[2292],{"nctId":2293,"briefTitle":2294,"status":197,"phases":2295,"primaryCompletion":1999,"completion":1998,"start":1562,"enrollment":224,"conditions":2296,"interventions":2303},"NCT01587131","DNA-based Influenza Vaccine in the Elderly",[87],[2297,2298,2299,2300,2301,2302],"Influenza, Human","Orthomyxoviridae Infections","RNA Virus Infections","Virus Diseases","Respiratory Tract Infections","Respiratory Tract Diseases",[2286],{"trials":2305,"activeCount":98},[],{"trials":2307,"activeCount":98},[],{"trials":2309,"activeCount":98},[],{"trials":2311,"activeCount":98},[],{"intervention":2313,"totalTrials":94,"cells":2314},"Prazosin",{"EARLY_PHASE1":2315,"PHASE1":2317,"PHASE2":2329,"PHASE3":2331,"PHASE4":2333,"NA":2335},{"trials":2316,"activeCount":98},[],{"trials":2318,"activeCount":98},[2319],{"nctId":2320,"briefTitle":2321,"status":2322,"phases":2323,"primaryCompletion":2324,"completion":2324,"start":2325,"enrollment":328,"conditions":2326,"interventions":2328},"NCT03894345","Prazosin Use in Adults With Anxiety Disorders","SUSPENDED",[87],"2023-12","2019-05-24",[18,2327],"Anxiety Disorders",[2313],{"trials":2330,"activeCount":98},[],{"trials":2332,"activeCount":98},[],{"trials":2334,"activeCount":98},[],{"trials":2336,"activeCount":98},[],{"intervention":2338,"totalTrials":94,"cells":2339},"Platelet-Rich-Plasma",{"EARLY_PHASE1":2340,"PHASE1":2342,"PHASE2":2353,"PHASE3":2355,"PHASE4":2357,"NA":2359},{"trials":2341,"activeCount":98},[],{"trials":2343,"activeCount":98},[2344],{"nctId":2345,"briefTitle":2346,"status":1027,"phases":2347,"primaryCompletion":2348,"completion":2348,"start":2349,"enrollment":391,"conditions":2350,"interventions":2352},"NCT06264635","Evaluating the Efficacy of Platelet-Rich-Plasma (PRP) for Erectile Dysfunction",[87],"2025-03","2025-01-24",[2351],"Erectile Dysfunction",[2338],{"trials":2354,"activeCount":98},[],{"trials":2356,"activeCount":98},[],{"trials":2358,"activeCount":98},[],{"trials":2360,"activeCount":98},[],{"intervention":2362,"totalTrials":94,"cells":2363},"Truvada",{"EARLY_PHASE1":2364,"PHASE1":2377,"PHASE2":2379,"PHASE3":2381,"PHASE4":2383,"NA":2385},{"trials":2365,"activeCount":98},[2366],{"nctId":2367,"briefTitle":2368,"status":197,"phases":2369,"primaryCompletion":2370,"completion":2371,"start":2372,"enrollment":2373,"conditions":2374,"interventions":2376},"NCT02148094","Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) for Sex Workers in India",[86],"2018-04-30","2018-06-30","2016-01",1325,[2375],"HIV Infection",[2362],{"trials":2378,"activeCount":98},[],{"trials":2380,"activeCount":98},[],{"trials":2382,"activeCount":98},[],{"trials":2384,"activeCount":98},[],{"trials":2386,"activeCount":98},[],{"intervention":2388,"totalTrials":173,"cells":2389},"Amantadine",{"EARLY_PHASE1":2390,"PHASE1":2392,"PHASE2":2394,"PHASE3":2396,"PHASE4":2398,"NA":2400},{"trials":2391,"activeCount":98},[],{"trials":2393,"activeCount":98},[],{"trials":2395,"activeCount":98},[],{"trials":2397,"activeCount":98},[],{"trials":2399,"activeCount":98},[],{"trials":2401,"activeCount":98},[2402,2410],{"nctId":2403,"briefTitle":2404,"status":197,"phases":2405,"primaryCompletion":1264,"completion":1264,"start":2406,"enrollment":328,"conditions":2407,"interventions":2409},"NCT01467258","Urinary Excretion of Acetylamantadine by Normal Healthy Volunteers",[91],"2011-11",[2408],"Healthy Metabolism",[2388],{"nctId":2411,"briefTitle":2412,"status":1027,"phases":2413,"primaryCompletion":2414,"completion":2414,"start":2415,"enrollment":669,"conditions":2416,"interventions":2417},"NCT02277938","Acetylamantadine Excretion by Cancer Patients",[],"2021-12","2013-08",[394],[2388],{"intervention":2419,"totalTrials":173,"cells":2420},"Ezetimibe",{"EARLY_PHASE1":2421,"PHASE1":2423,"PHASE2":2425,"PHASE3":2427,"PHASE4":2429,"NA":2431},{"trials":2422,"activeCount":98},[],{"trials":2424,"activeCount":98},[],{"trials":2426,"activeCount":98},[],{"trials":2428,"activeCount":98},[],{"trials":2430,"activeCount":98},[],{"trials":2432,"activeCount":98},[2433,2441],{"nctId":2434,"briefTitle":2435,"status":197,"phases":2436,"primaryCompletion":2415,"completion":2437,"start":1264,"enrollment":30,"conditions":2438,"interventions":2440},"NCT01584206","Sitosterolemia Metabolism",[91],"2016-12",[2439],"Sitosterolemia",[2419],{"nctId":2442,"briefTitle":2443,"status":197,"phases":2444,"primaryCompletion":2066,"completion":739,"start":2445,"enrollment":391,"conditions":2446,"interventions":2448},"NCT00955227","Can Cholesterol Lowering Drugs Influence Circulating Omega-3 Fatty Acid Levels",[91],"2009-07",[29,2447],"Hyperlipidemia",[2419],{"intervention":2450,"totalTrials":94,"cells":2451},"cardiovascular and respiratory systems monitoring",{"EARLY_PHASE1":2452,"PHASE1":2454,"PHASE2":2456,"PHASE3":2458,"PHASE4":2460,"NA":2462},{"trials":2453,"activeCount":98},[],{"trials":2455,"activeCount":98},[],{"trials":2457,"activeCount":98},[],{"trials":2459,"activeCount":98},[],{"trials":2461,"activeCount":98},[],{"trials":2463,"activeCount":98},[2464],{"nctId":2465,"briefTitle":2466,"status":1027,"phases":2467,"primaryCompletion":2468,"completion":2469,"start":2134,"enrollment":328,"conditions":2470,"interventions":2471},"NCT04644341","Tele-monitoring of COVID-19 Survivors for Long-Term Impacts",[],"2021-08-31","2021-11-01",[203],[2450],{"intervention":2473,"totalTrials":94,"cells":2474},"Colesevelam",{"EARLY_PHASE1":2475,"PHASE1":2477,"PHASE2":2479,"PHASE3":2481,"PHASE4":2483,"NA":2485},{"trials":2476,"activeCount":98},[],{"trials":2478,"activeCount":98},[],{"trials":2480,"activeCount":98},[],{"trials":2482,"activeCount":98},[],{"trials":2484,"activeCount":98},[],{"trials":2486,"activeCount":98},[2487],{"nctId":2488,"briefTitle":2489,"status":1027,"phases":2490,"primaryCompletion":2491,"completion":2492,"start":2493,"enrollment":2494,"conditions":2495,"interventions":2496},"NCT01948648","Effects of Fish Oil and Colesevelam (STAIR7007)",[91],"2021-04-30","2021-07-30","2018-02-06",13,[2439],[2473,2497],"Combination of fish oil and colesevelam",{"intervention":2497,"totalTrials":94,"cells":2499},{"EARLY_PHASE1":2500,"PHASE1":2502,"PHASE2":2504,"PHASE3":2506,"PHASE4":2508,"NA":2510},{"trials":2501,"activeCount":98},[],{"trials":2503,"activeCount":98},[],{"trials":2505,"activeCount":98},[],{"trials":2507,"activeCount":98},[],{"trials":2509,"activeCount":98},[],{"trials":2511,"activeCount":98},[2512],{"nctId":2488,"briefTitle":2489,"status":1027,"phases":2513,"primaryCompletion":2491,"completion":2492,"start":2493,"enrollment":2494,"conditions":2514,"interventions":2515},[91],[2439],[2473,2497],{"intervention":2517,"totalTrials":94,"cells":2518},"ASA 81mg",{"EARLY_PHASE1":2519,"PHASE1":2521,"PHASE2":2523,"PHASE3":2525,"PHASE4":2527,"NA":2529},{"trials":2520,"activeCount":98},[],{"trials":2522,"activeCount":98},[],{"trials":2524,"activeCount":98},[],{"trials":2526,"activeCount":98},[],{"trials":2528,"activeCount":98},[],{"trials":2530,"activeCount":98},[2531],{"nctId":2532,"briefTitle":2533,"status":1027,"phases":2534,"primaryCompletion":2535,"completion":58,"start":2536,"enrollment":2537,"conditions":2538,"interventions":2540},"NCT03629327","Inducing Immune Quiescence the Genital Tract With ASA",[91],"2024-09-30","2022-01-10",300,[2539],"HIV",[2517,2541],"ASA 325mg",{"intervention":2541,"totalTrials":94,"cells":2543},{"EARLY_PHASE1":2544,"PHASE1":2546,"PHASE2":2548,"PHASE3":2550,"PHASE4":2552,"NA":2554},{"trials":2545,"activeCount":98},[],{"trials":2547,"activeCount":98},[],{"trials":2549,"activeCount":98},[],{"trials":2551,"activeCount":98},[],{"trials":2553,"activeCount":98},[],{"trials":2555,"activeCount":98},[2556],{"nctId":2532,"briefTitle":2533,"status":1027,"phases":2557,"primaryCompletion":2535,"completion":58,"start":2536,"enrollment":2537,"conditions":2558,"interventions":2559},[91],[2539],[2517,2541],{"intervention":2561,"totalTrials":94,"cells":2562},"Acetylsalicylic Acid",{"EARLY_PHASE1":2563,"PHASE1":2565,"PHASE2":2567,"PHASE3":2569,"PHASE4":2571,"NA":2573},{"trials":2564,"activeCount":98},[],{"trials":2566,"activeCount":98},[],{"trials":2568,"activeCount":98},[],{"trials":2570,"activeCount":98},[],{"trials":2572,"activeCount":98},[],{"trials":2574,"activeCount":98},[2575],{"nctId":2576,"briefTitle":2577,"status":197,"phases":2578,"primaryCompletion":739,"completion":2579,"start":2580,"enrollment":2581,"conditions":2582,"interventions":2583},"NCT02079077","Inducing Immune Quiescence to Prevent HIV Infection in Women",[91],"2018-01-01","2014-04",91,[2539],[2561,2584],"Hydroxychloroquine",{"intervention":2584,"totalTrials":94,"cells":2586},{"EARLY_PHASE1":2587,"PHASE1":2589,"PHASE2":2591,"PHASE3":2593,"PHASE4":2595,"NA":2597},{"trials":2588,"activeCount":98},[],{"trials":2590,"activeCount":98},[],{"trials":2592,"activeCount":98},[],{"trials":2594,"activeCount":98},[],{"trials":2596,"activeCount":98},[],{"trials":2598,"activeCount":98},[2599],{"nctId":2576,"briefTitle":2577,"status":197,"phases":2600,"primaryCompletion":739,"completion":2579,"start":2580,"enrollment":2581,"conditions":2601,"interventions":2602},[91],[2539],[2561,2584],{"intervention":2604,"totalTrials":94,"cells":2605},"Lidocaine",{"EARLY_PHASE1":2606,"PHASE1":2608,"PHASE2":2610,"PHASE3":2612,"PHASE4":2614,"NA":2616},{"trials":2607,"activeCount":98},[],{"trials":2609,"activeCount":98},[],{"trials":2611,"activeCount":98},[],{"trials":2613,"activeCount":98},[],{"trials":2615,"activeCount":98},[],{"trials":2617,"activeCount":98},[2618],{"nctId":2619,"briefTitle":2620,"status":433,"phases":2621,"primaryCompletion":1264,"start":2622,"enrollment":24,"conditions":2623,"interventions":2625},"NCT00523055","Ultrasound-guided Supraclavicular Brachial Plexus Blockade",[91],"2008-05",[2624],"Pain",[2604],{"intervention":2627,"totalTrials":94,"cells":2628},"Intrathecal bupivacaine and morphine",{"EARLY_PHASE1":2629,"PHASE1":2631,"PHASE2":2633,"PHASE3":2635,"PHASE4":2637,"NA":2639},{"trials":2630,"activeCount":98},[],{"trials":2632,"activeCount":98},[],{"trials":2634,"activeCount":98},[],{"trials":2636,"activeCount":98},[],{"trials":2638,"activeCount":98},[],{"trials":2640,"activeCount":98},[2641],{"nctId":2642,"briefTitle":2643,"status":1027,"phases":2644,"primaryCompletion":2645,"completion":2645,"start":2646,"enrollment":224,"conditions":2647,"interventions":2649},"NCT05374356","High Spinal Anesthesia and the Incidence of Delirium After Cardiac Surgery",[91],"2024-06-30","2022-05-02",[2648],"Post-Operative Confusion",[2627],{"intervention":2651,"totalTrials":94,"cells":2652},"25% Human Serum Albumin",{"EARLY_PHASE1":2653,"PHASE1":2655,"PHASE2":2657,"PHASE3":2659,"PHASE4":2661,"NA":2663},{"trials":2654,"activeCount":98},[],{"trials":2656,"activeCount":98},[],{"trials":2658,"activeCount":98},[],{"trials":2660,"activeCount":98},[],{"trials":2662,"activeCount":98},[],{"trials":2664,"activeCount":98},[2665],{"nctId":2666,"briefTitle":2667,"status":197,"phases":2668,"primaryCompletion":2669,"completion":2670,"start":1666,"enrollment":173,"conditions":2671,"interventions":2674},"NCT02975726","Peritoneal Dialysis Catheters for the Treatment of Refractory Ascites",[91],"2018-05","2019-02",[2672,2673],"Liver Cirrhosis","Ascites",[2651],{"intervention":2676,"totalTrials":94,"cells":2677},"Misoprostol",{"EARLY_PHASE1":2678,"PHASE1":2680,"PHASE2":2682,"PHASE3":2684,"PHASE4":2686,"NA":2688},{"trials":2679,"activeCount":98},[],{"trials":2681,"activeCount":98},[],{"trials":2683,"activeCount":98},[],{"trials":2685,"activeCount":98},[],{"trials":2687,"activeCount":98},[],{"trials":2689,"activeCount":98},[2690],{"nctId":2691,"briefTitle":2692,"status":197,"phases":2693,"primaryCompletion":1530,"completion":1530,"start":2694,"enrollment":2695,"conditions":2696,"interventions":2698},"NCT01070472","Efficacy and Safety of Titrated Oral Misoprostol Solution for Labor Induction at Term",[91],"2010-03",250,[2697],"Labor Induction at Term",[2676],{"intervention":2700,"totalTrials":94,"cells":2701},"covid19 vaccine",{"EARLY_PHASE1":2702,"PHASE1":2704,"PHASE2":2706,"PHASE3":2708,"PHASE4":2710,"NA":2712},{"trials":2703,"activeCount":98},[],{"trials":2705,"activeCount":98},[],{"trials":2707,"activeCount":98},[],{"trials":2709,"activeCount":98},[],{"trials":2711,"activeCount":98},[],{"trials":2713,"activeCount":98},[2714],{"nctId":2715,"briefTitle":2716,"status":1027,"phases":2717,"primaryCompletion":2718,"completion":2414,"start":2719,"enrollment":2720,"conditions":2721,"interventions":2723},"NCT04713163","COVID-19 Vaccine Induced Immunity",[],"2021-04","2021-01",200,[2722],"Covid19",[2700],{"intervention":2725,"totalTrials":94,"cells":2726},"Subcut. + Subconj. Xylocaine",{"EARLY_PHASE1":2727,"PHASE1":2729,"PHASE2":2731,"PHASE3":2733,"PHASE4":2735,"NA":2737},{"trials":2728,"activeCount":98},[],{"trials":2730,"activeCount":98},[],{"trials":2732,"activeCount":98},[],{"trials":2734,"activeCount":98},[],{"trials":2736,"activeCount":98},[],{"trials":2738,"activeCount":98},[2739],{"nctId":2740,"briefTitle":2741,"status":1027,"phases":2742,"primaryCompletion":2743,"completion":2744,"start":2745,"enrollment":965,"conditions":2746,"interventions":2749},"NCT02959697","Subconjunctival Injection of Local Anesthetic in Anterior Blepharoptosis Repair",[91],"2023-05-01","2023-06-01","2017-09-01",[2747,2748],"Blepharoptosis","Ptosis",[2725,2750],"Subcut. + Sham Subconj.",{"intervention":2750,"totalTrials":94,"cells":2752},{"EARLY_PHASE1":2753,"PHASE1":2755,"PHASE2":2757,"PHASE3":2759,"PHASE4":2761,"NA":2763},{"trials":2754,"activeCount":98},[],{"trials":2756,"activeCount":98},[],{"trials":2758,"activeCount":98},[],{"trials":2760,"activeCount":98},[],{"trials":2762,"activeCount":98},[],{"trials":2764,"activeCount":98},[2765],{"nctId":2740,"briefTitle":2741,"status":1027,"phases":2766,"primaryCompletion":2743,"completion":2744,"start":2745,"enrollment":965,"conditions":2767,"interventions":2768},[91],[2747,2748],[2725,2750],{"intervention":2770,"totalTrials":94,"cells":2771},"Acetaminophen and Ibuprofen",{"EARLY_PHASE1":2772,"PHASE1":2774,"PHASE2":2776,"PHASE3":2778,"PHASE4":2780,"NA":2782},{"trials":2773,"activeCount":98},[],{"trials":2775,"activeCount":98},[],{"trials":2777,"activeCount":98},[],{"trials":2779,"activeCount":98},[],{"trials":2781,"activeCount":98},[],{"trials":2783,"activeCount":98},[2784],{"nctId":2785,"briefTitle":2786,"status":1027,"phases":2787,"primaryCompletion":2788,"completion":1999,"start":1066,"enrollment":224,"conditions":2789,"interventions":2791},"NCT01605240","Ibuprofen Versus Codeine. Is One Better for Post-operative Pain Relief Following Reduction of Paediatric Forearm Fractures?",[91],"2013-12",[2790,2624],"Fracture",[2770,2792],"Acetaminophen and Codeine",{"intervention":2792,"totalTrials":94,"cells":2794},{"EARLY_PHASE1":2795,"PHASE1":2797,"PHASE2":2799,"PHASE3":2801,"PHASE4":2803,"NA":2805},{"trials":2796,"activeCount":98},[],{"trials":2798,"activeCount":98},[],{"trials":2800,"activeCount":98},[],{"trials":2802,"activeCount":98},[],{"trials":2804,"activeCount":98},[],{"trials":2806,"activeCount":98},[2807],{"nctId":2785,"briefTitle":2786,"status":1027,"phases":2808,"primaryCompletion":2788,"completion":1999,"start":1066,"enrollment":224,"conditions":2809,"interventions":2810},[91],[2790,2624],[2770,2792],{"intervention":2812,"totalTrials":94,"cells":2813},"Oseltamivir 75 mg",{"EARLY_PHASE1":2814,"PHASE1":2816,"PHASE2":2818,"PHASE3":2820,"PHASE4":2822,"NA":2824},{"trials":2815,"activeCount":98},[],{"trials":2817,"activeCount":98},[],{"trials":2819,"activeCount":98},[],{"trials":2821,"activeCount":98},[],{"trials":2823,"activeCount":98},[],{"trials":2825,"activeCount":98},[2826],{"nctId":2827,"briefTitle":2828,"status":2108,"phases":2829,"primaryCompletion":2445,"completion":2445,"start":1359,"enrollment":98,"conditions":2830,"interventions":2833},"NCT00844155","Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir in the Intensive Care Unit",[91],[2831,2832],"Influenza A Virus Infection","Influenza B Virus Infection",[2812],{"intervention":2835,"totalTrials":94,"cells":2836},"desflurane",{"EARLY_PHASE1":2837,"PHASE1":2839,"PHASE2":2841,"PHASE3":2843,"PHASE4":2845,"NA":2847},{"trials":2838,"activeCount":98},[],{"trials":2840,"activeCount":98},[],{"trials":2842,"activeCount":98},[],{"trials":2844,"activeCount":98},[],{"trials":2846,"activeCount":98},[],{"trials":2848,"activeCount":98},[2849],{"nctId":2850,"briefTitle":2851,"status":1027,"phases":2852,"primaryCompletion":2788,"completion":2788,"start":1221,"enrollment":340,"conditions":2853,"interventions":2855},"NCT01726725","Hemifacial Spasm and Desflurane",[],[2854],"Hemifacial Spasm",[2835],{"intervention":2857,"totalTrials":94,"cells":2858},"Rituximab",{"EARLY_PHASE1":2859,"PHASE1":2861,"PHASE2":2863,"PHASE3":2865,"PHASE4":2867,"NA":2869},{"trials":2860,"activeCount":98},[],{"trials":2862,"activeCount":98},[],{"trials":2864,"activeCount":98},[],{"trials":2866,"activeCount":98},[],{"trials":2868,"activeCount":98},[],{"trials":2870,"activeCount":98},[2871],{"nctId":2872,"briefTitle":2873,"status":197,"phases":2874,"primaryCompletion":2875,"completion":2875,"start":2042,"enrollment":2876,"conditions":2877,"interventions":2879},"NCT00963703","Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid Arthritis",[91],"2012-03",15,[2878],"Rheumatoid Arthritis",[2857],{"intervention":2881,"totalTrials":94,"cells":2882},"Cefazolin",{"EARLY_PHASE1":2883,"PHASE1":2885,"PHASE2":2887,"PHASE3":2889,"PHASE4":2891,"NA":2893},{"trials":2884,"activeCount":98},[],{"trials":2886,"activeCount":98},[],{"trials":2888,"activeCount":98},[],{"trials":2890,"activeCount":98},[],{"trials":2892,"activeCount":98},[],{"trials":2894,"activeCount":98},[2895],{"nctId":2896,"briefTitle":2897,"status":197,"phases":2898,"primaryCompletion":2899,"completion":2899,"start":2900,"enrollment":1291,"conditions":2901,"interventions":2904},"NCT04319328","Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?",[],"2024-04-30","2019-10-18",[2902,2903,1576],"Hemodialysis Complication","Infectious Disease",[2881,2905],"Ceftazidime",{"intervention":2905,"totalTrials":94,"cells":2907},{"EARLY_PHASE1":2908,"PHASE1":2910,"PHASE2":2912,"PHASE3":2914,"PHASE4":2916,"NA":2918},{"trials":2909,"activeCount":98},[],{"trials":2911,"activeCount":98},[],{"trials":2913,"activeCount":98},[],{"trials":2915,"activeCount":98},[],{"trials":2917,"activeCount":98},[],{"trials":2919,"activeCount":98},[2920],{"nctId":2896,"briefTitle":2897,"status":197,"phases":2921,"primaryCompletion":2899,"completion":2899,"start":2900,"enrollment":1291,"conditions":2922,"interventions":2923},[],[2902,2903,1576],[2881,2905],{"intervention":2925,"totalTrials":94,"cells":2926},"Heparin 1000 u \u002F ml",{"EARLY_PHASE1":2927,"PHASE1":2929,"PHASE2":2931,"PHASE3":2933,"PHASE4":2935,"NA":2937},{"trials":2928,"activeCount":98},[],{"trials":2930,"activeCount":98},[],{"trials":2932,"activeCount":98},[],{"trials":2934,"activeCount":98},[],{"trials":2936,"activeCount":98},[],{"trials":2938,"activeCount":98},[2939],{"nctId":2940,"briefTitle":2941,"status":197,"phases":2942,"primaryCompletion":740,"completion":740,"start":2943,"enrollment":1291,"conditions":2944,"interventions":2947},"NCT01394458","Efficacy and Safety of an Ethanol\u002FSodium Citrate Locking Solution: A Pilot Study",[91],"2011-08",[2945,2946],"Catheter Related Infection","Bacteremia",[2925],{"intervention":747,"totalTrials":94,"cells":2949},{"EARLY_PHASE1":2950,"PHASE1":2952,"PHASE2":2954,"PHASE3":2956,"PHASE4":2958,"NA":2960},{"trials":2951,"activeCount":98},[],{"trials":2953,"activeCount":98},[],{"trials":2955,"activeCount":98},[],{"trials":2957,"activeCount":98},[],{"trials":2959,"activeCount":98},[],{"trials":2961,"activeCount":98},[2962],{"nctId":735,"briefTitle":736,"status":433,"phases":2963,"primaryCompletion":738,"completion":739,"start":740,"enrollment":437,"conditions":2964,"interventions":2965},[91],[742,743,744,745],[747,748,703,749],{"intervention":748,"totalTrials":94,"cells":2967},{"EARLY_PHASE1":2968,"PHASE1":2970,"PHASE2":2972,"PHASE3":2974,"PHASE4":2976,"NA":2978},{"trials":2969,"activeCount":98},[],{"trials":2971,"activeCount":98},[],{"trials":2973,"activeCount":98},[],{"trials":2975,"activeCount":98},[],{"trials":2977,"activeCount":98},[],{"trials":2979,"activeCount":98},[2980],{"nctId":735,"briefTitle":736,"status":433,"phases":2981,"primaryCompletion":738,"completion":739,"start":740,"enrollment":437,"conditions":2982,"interventions":2983},[91],[742,743,744,745],[747,748,703,749],{"intervention":749,"totalTrials":94,"cells":2985},{"EARLY_PHASE1":2986,"PHASE1":2988,"PHASE2":2990,"PHASE3":2992,"PHASE4":2994,"NA":2996},{"trials":2987,"activeCount":98},[],{"trials":2989,"activeCount":98},[],{"trials":2991,"activeCount":98},[],{"trials":2993,"activeCount":98},[],{"trials":2995,"activeCount":98},[],{"trials":2997,"activeCount":98},[2998],{"nctId":735,"briefTitle":736,"status":433,"phases":2999,"primaryCompletion":738,"completion":739,"start":740,"enrollment":437,"conditions":3000,"interventions":3001},[91],[742,743,744,745],[747,748,703,749],{"intervention":3003,"totalTrials":94,"cells":3004},"Control",{"EARLY_PHASE1":3005,"PHASE1":3007,"PHASE2":3009,"PHASE3":3011,"PHASE4":3013,"NA":3015},{"trials":3006,"activeCount":98},[],{"trials":3008,"activeCount":98},[],{"trials":3010,"activeCount":98},[],{"trials":3012,"activeCount":98},[],{"trials":3014,"activeCount":98},[],{"trials":3016,"activeCount":98},[3017],{"nctId":3018,"briefTitle":3019,"status":197,"phases":3020,"primaryCompletion":3021,"completion":3021,"start":2580,"enrollment":1291,"conditions":3022,"interventions":3024},"NCT02112422","The Role of Timing of Dexamethasone Administration on Pain Scores and Quality of Recovery in Cesarean Section.",[91],"2014-11",[3023],"Pregnancy",[3003,3025],"Intervention",{"intervention":3025,"totalTrials":94,"cells":3027},{"EARLY_PHASE1":3028,"PHASE1":3030,"PHASE2":3032,"PHASE3":3034,"PHASE4":3036,"NA":3038},{"trials":3029,"activeCount":98},[],{"trials":3031,"activeCount":98},[],{"trials":3033,"activeCount":98},[],{"trials":3035,"activeCount":98},[],{"trials":3037,"activeCount":98},[],{"trials":3039,"activeCount":98},[3040],{"nctId":3018,"briefTitle":3019,"status":197,"phases":3041,"primaryCompletion":3021,"completion":3021,"start":2580,"enrollment":1291,"conditions":3042,"interventions":3043},[91],[3023],[3003,3025]]